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N-acylphosphatidylethanolamines are a class of phospholipids present at low 
concentrations in cellular membranes1. They have been studied as fatty-acid 
ethanolamine (FAEs) precursors, given FAEs bioactive effects such as control of 
inflammation2, pain sensation and neuroprotection3 as well as control of food 
intake4.  
However, NAPEs may also have biological functions of their own: they might 
participate in the control of membrane fluidics5, organization of lipid raft5, 
arrangement of cell division site domains7 and protein anchorage. 
Evidence indicates that NAPEs are produced in the brain following injurious stimuli 
of diverse nature. Ischemia8, excitotoxicity9 as well as toxic molecules including 
sodium azide10, glutamate11 and ethanol12 may all cause NAPE accumulation. 
In this context, we have recently observed that this lipid molecules are increased 
following the administration of the neurotoxin 6-hydroxydopamine in mice13, a widely 
used model of Parkinson’s disease. 
Parkinson’s disease is a chronic progressive neurodegenerative disease 
caused by the loss of the nigrostriatal dopaminergic neurons14, which results in an 
impairment of the control of voluntary movements, leading to a motor 
symptomatology that includes bradykinesia, rest tremor, rigidity and postural 
disturbances15. 
Parkinson’s disease as well as other neurodegenerative diseases represent a 
substantial burden for public health, given the fact that worldwide population is 
getting older and these pathologies mostly affect elderly people. Unfortunately to 
date no therapies have been developed to cure neurodegenerative disease. Thus, 
there is the need to understand in greater depth Parkinson’s disease 
pathophysiology and to further develop new therapeutic approaches for this 
condition. 
The aim of the present work was to elucidate whether and how NAPE production is 
involved in the neurodegenerative process. 
Using a combination of genetic, pharmacological and behavioral techniques, I was 
able to show that locally produced NAPEs exert protective effects against 6-OHDA-
induced toxicity by regulating the expression and activity of LRRK2, a multifunctional 
protein that is known to be involved in both familial and sporadic Parkinson’s. 
The evidence collected in my experiments may thus provide a starting point 
for the development of new therapeutic approaches for neurodegenerative disease, 
as well as for the identification of biological markers useful in the early detection of 





N-acylphosphatidylethanolamines are triacylated phospholipids derived from 
phosphatidylethanolamine (PE) with a third, N-linked fatty acyl chain16, generally 
referred to by the acronym NAPE. Although in small amounts, NAPEs are a class of 
widely expressed glycerophospholipids, present in both eukaryotic, plant and animal 
cells, as well as in prokaryotic cells.  
Under physiological conditions, NAPEs represent only 0.01% of total phospholipids, 
with levels in the range of nmol/g of wet tissue, and a little higher expression in the 
brain. Besides the brain, they are found in other organs such as spinal cord, testis 
and spleen as well as physiological fluids17. NAPEs are located in cellular 
membranes and are more abundant in the plasma membrane than in intracellular 
ones1. Furthermore, they have been detected in human plasma where they are 
probably associated with the outer phospholipid shell of lipoproteins18.  
 1.1 NAPE biosynthesis 
The canonical pathways for the biosynthesis and hydrolysis of NAPE species 
were thought to be relatively simple, however recent studies have shown that the 
pathways are more complicated than expected, as every reaction is often catalyzed 
by diverse enzymes or isoenzymes. 
 Figure 1: Biosynthetic and catabolic pathway of NAPE. 
NAPE biosynthesis, as summarized in Fig. 1, consists in the transfer of a fatty acyl 
chain from sn-1 position of a donor glycerophospholipid molecule such as 
phosphatidylcholine (PC) to the primary amino group of phosphatidylethanolamine 
(PE) by the action of the Ca2+-dependent enzyme N-Acyltransferase (Ca-NAT)19. 
This enzyme is an integral membrane protein16 found in mammalian tissue including 
brain20, heart and testis. Among various brain regions in rat, the highest activity of 
Ca-NAT was observed in brainstem, followed by intermediate activity in the striatum 
among other areas20. Ca-NAT does not discriminate based on the length or 
unsaturation of the transferred acid chain. This is why saturated fatty acyl chains 
(abundant in the sn-1 position of glycerophospholipids) are preferred over 
polyunsaturated fatty acyl chains (abundant in the sn-2 position) as the molecular 
species of N-acyl groups of NAPE21. 
Another Ca2+-independent pathway for NAPEs synthesis has been discovered22: five 
members of the HRAS-like suppressor (HRASLS) superfamily possess 
phospholipid-metabolizing activities including NAPE-forming N-acyltransferase 
activity, which releases an acyl group from the sn-1 or sn-2 position of PC to PE in a 
Ca2+-independent manner. These enzymes also have O-acyltransferase activity, 
which transfers an acyl group from PC to the hydroxyl group of lyso-PC as well as 
PLA1/A2 activity, which hydrolyzes the sn-1 or sn-2 ester bonds of PC or PE.  
They have been denominated phospholipase A/acyltransferase (PLA/AT)-1-5. The 
PLA/AT-1, PLA/AT-2 and PLA/AT-5 isoforms showed higher N-acyltransferase 
activities over PLA1/A2 activities compared to PLA/AT-3 and PLA/AT-4. All five 
HRASLS enzymes are expressed in testis, liver, adipose tissue and kidney, but in 
contrast to Ca-NAT, their brain levels are low23. 
1.2 NAPE hydrolysis 
The hydrolysis of NAPEs occurs via multiple enzyme-mediated routes (Fig. 
1). The primary pathway consists in the release of their third acyl chain (N), and the 
simultaneous formation of fatty acid ethanolamides (FAE) and phosphatidic acid, 
through the action of N-acyl phosphatidylethanolamine-specific phospholipase D 
(NAPE-PLD)24. Depending on the length and the saturation of the acyl chain, 
diverse FAEs can be produced, as illustrated in Fig. 2. The fatty acid composition of 
the N-acyl group is dominated by saturated fatty acids (palmitic and stearic acid, 
16:0 and 18:0, respectively) and to a lesser extent oleic acid 18:1, while arachidonic 
acid 20:4 usually accounts for 0.4-0.6% of the fatty acids21. FAEs include 
anandamide (AEA), palmitoylethanolamide (PEA), oleoylethanolamide (OEA) and 
stearoylethanolamide (SEA). All of them are important signaling molecules, having a 
variety of biological effects, including control of food intake, inflammation, pain 
sensation, and neuroprotection. 
PEA is made of a saturated 16 carbon chain, and shows anti-inflammatory, 
analgesic and neuroprotective actions through its binding to peroxisome proliferator-
activated receptor- (PPAR-)2; PPAR-α is also a target for OEA, a lipid composed 
by a monounsaturated chain of 18 carbons, that regulates satiety, body weight and 
cancer cell proliferation4; SEA is made by a saturated 18 carbons chain, and was 
shown to be pro-apoptotic and anorexic16; AEA, the least abundant FAE, contains a 
polyunsaturated acyl chain of 20 carbons and 4 double bonds (20:4) and acts as a 
CB1 agonist to induce analgesia, neuroprotection, hypotension and appetite 
stimulation16. 
 
Figure 2: FAE generation from NAPEs. The sn1, 2 and 3 chains indicated in the picture are 
representative. The sn1 chain can be composed of 16:0, 18:0, 18:1 and 18:2, with 18:0 as the most 
abundant. Sn2 may be shows 14:0, 16:0, 18:0, 18:1, 18:2, 20:4 and 22:6, where 20:4 is the most 
expressed in nature. Sn3 when released by NAPE-PLD action give rise to FAEs, among others the 
most expressed and biological active are palmitoylethanolamine (16:0), stearoylethanolamine (18:0), 
oleoylethanolamine (18:1) and anandamide (20:4). 
NAPE-PLD is a member of the zinc metallohydrolase family of the -lactamase24, 
with a structure unrelated to any other PLD isoforms. NAPE-PLD is ubiquitously 
expressed at high levels in testis, kidney and brain24. The crystal structure of NAPE-
PLD was obtained in our laboratory and reveals that the enzyme is tightly bound to 
microsomal and mitochondrial membranes through an extended lipid-binding 
surface spanning the NAPE-PLD dimer. Moreover, this enzyme shows a 
hydrophobic nook facing the lipid bilayer that provides a recognition filter: NAPE-
PLD is highly specific for NAPEs without any selectivity for their N-acyl moieties25. 
Thus, its major physiological role appears to be non-specific formation of various 
FAEs including bioactive species.  
The physiological regulators of NAPE-PLD activity are still unknown, and there is no 
evidence that the increase in intracellular Ca2+ concentration stimulates this activity. 
However, it has been shown that the proinflammatory bacterial endotoxin 
lipopolysaccharide (LPS) suppresses the expression of NAPE-PLD and 
consequently down-regulates PEA biosynthesis in a human macrophage cell line26.  
The conversion from NAPE to FAE can occur also through multi-step pathways with 
the formation of an intermediate metabolite N-acylated lysophospholipids (lyso-
NAPE)27. In these NAPE-PLD-independent pathways, an O-acyl chain of NAPE is 
eliminated to form lyso-NAPE, which is then subjected to the hydrolysis of the 
phosphodiester bond to generate FAE and lysophosphatidic acid (LPA). 
Alternatively, lyso-NAPE is further O-deacylated to form glycerophospho-FAE (GP-
FAE), followed by hydrolysis of the phosphodiester bond to generate FAE and 
glycerol-3-phosphate27. 
1.3 NAPE-PLD KO mice 
Ten years ago, Cravatt’s group generated NAPE-PLD knockout mice (NAPE-
PLD-/-)28. These mice were born according to the expected Mendelian frequency and 
were viable and healthy without overt abnormality in cage behavior28. Moreover 
NAPE-PLD-/- mice showed 5-15 fold higher levels of NAPEs with saturated and 
monounsaturated N-acyl groups in the brain. However, the detection of unaltered or 
moderately reduced FAEs levels confirmed the existence of the alternative 
pathways for the biosynthesis of FAEs as described above21. In accordance with the 
presence of these NAPE-PLD-independent pathways, the brain of NAPE-PLD-/- 
mice showed a remarkable increase in endogenous levels of lyso-NAPE and GP-
FAE as well as NAPE21. Moreover, deacylation of NAPE to lyso-NAPE could be 
catalyzed by secretory PLA2s or by /-hydrolase domain-containing protein 4 
(ABHD4). In addition, ABHD4 can further deacylate lyso-NAPE to produce GP-FAE. 
Glycerophosphodiester phosphodiesterase 1 (GDE1) mediates the hydrolysis of 
GP-FAE, resulting in the formation of FAE and glycerol-3-phosphate29.  
Double knockout mice of GDE1 and NAPE-PLD were generated in Cravatt’s 
laboratory, and their brain levels of FAEs were compared with those of NAPE-PLD 
deficient mice30: interestingly, no differences were found between these mice. These 
results suggested the involvement of other enzymes in the NAPE-PLD-independent 
route. Indeed, there is a multi-step pathway to generate FAE through phospholipase 
C (PLC)-phosphatase activity. NAPE is hydrolyzed to produce FAE-phosphate, 
followed by dephosphorylation to generate FAE. Consistent with this signal route, 
mouse macrophage cells treated with LPS showed elevated levels of anandamide 
even though NAPE-PLD was downregulated31. PTPN22 and SHIP1 (Src homology 
2 domain-containing inositol-5-phosphatase 1) were shown to exhibit phosphatase 
activity that produce anandamide from anandamide phosphate16. 
1.4 NAPE functions 
NAPEs not only serve as precursors to FAEs, but also have biological 
functions on their own, as depicted in Fig. 3. First, NAPEs seems to work in 
membrane stabilization5. Indeed, the N-acyl chain of NAPE may be embedded in 
the membrane bilayer giving to this lipid a more membrane stabilizing structure than 
PE from which it derived. Having a negative charge, NAPE may lead to 
physiological functions in anchoring or activating various intracellular proteins17. 
Moreover, NAPEs do not seem to form cholesterol-rich domains, but they can 
displace cholesterol from cholesterol-sphingomyelin domains. Thus, when NAPEs 
are hydrolyzed to form FAEs, they may change cholesterol distribution in 
membranes, as FAEs can form 1:1 complexes with cholesterol. Furthermore, in 
Escherichia coli it has been shown that endogenously produced NAPEs, together 
with phosphatidic acid, are significantly enriched at the cell poles and division site 
domains, meaning that NAPEs may organize amphitropic cell division proteins at 
specific sites on the membrane surface7.  
 
Figure 3: Hypothetical NAPEs functions. NAPEs may be involved in membrane stabilization and 
organization; they interact with intracellular proteins, stabilizing their anchorage to the membrane or 
stimulating their activity; they are involved in the organization of cell division pole at the membrane, and 
inhibits pseudopod formation. 
 
Furthermore, NAPEs can block phagocytosis in macrophages, probably via 
inhibition of pseudopodia formation32.   
In addition, these lipids are interesting molecules in lipid based formulation for drug 
delivery17. Indeed, NAPEs can stabilize the lipid bilayer in liposomes preventing 
liposome leakage, or they can modify the permeability and impart fusogenicity to 
vesicles in a divalent cation dependent manner6. Specifically, in the presence of 
divalent cations NAPEs can flip in the membrane, inducing a deep insertion of the 
N-linked acyl chain in the bilayer that leads to a negative curvature of the membrane 
that facilitates fusion6.  
1.5 NAPEs in neurodegeneration  
NAPE levels strongly increase in response to stress conditions involving 
degenerative membrane changes. Thus, during myocardial ischemia significantly 
higher levels of NAPEs (mainly N-palmitoyl-PE and N-stearoyl-PE) were detected 
for the first time in dog heart33. Furthermore, increases in in vivo NAPE levels were 
reported in inflamed rat testis34 and in the uterus of pregnant mice35.  
NAPE production in the nervous system has been widely studied: NAPEs are 
increased in the brain following injurious stimuli of diverse nature. For instance, 
following post-decapitative ischemia, NAPE levels reach 1.5% of total phospholipids 
in the brain of young rats8,36. Many papers report that NAPE synthesis can also be 
triggered by the presence of toxic molecules. For example, in cultured neocortical 
neurons, sodium azide (mitochondrial respiratory chain inhibitor) induced an 
increase in NAPE levels that might be related to neuronal death10. The same effect 
has been observed in cultured cortical neurons when treated with glutamate11,37 and 
hydrogen peroxide. In vivo, neuronal death induced by ischemia36,38,39, by 
excitotoxicity (kainate and NMDA administration)9, or by high doses of ethanol12 
resulted in increased formation of NAPEs. Moreover, neuronal tissue from all 
investigated species has a large capacity for NAPEs production during injury-
induced calcium influx37,40.  
The accumulation of many species of NAPEs is generally restricted to area of 
neuronal cell death, as recently demonstrated using mass spectrometry imaging 
technique39. This phenomenon may be explained by the remarkable increase in 
intracellular Ca2+ concentration, which results in the activation of Ca-NAT. In support 
to this theory, also physiologically relevant Ca2+ spikes were reported to stimulate 
NAPE production in intact neurons20,41. It is still not clear whether PLA/AT-1 is 
involved in NAPE formation during cardiac infarction, brain ischemia, testicular 
inflammation or during physiological increases in intracellular Ca2+, given the fact 
that the enzyme activity of PLA/AT family is not enhanced by Ca2+ 16.  
It is worth of notice that in neonatal rats exposed to neurotoxic stimuli, NAPE levels 
in the brain can increase up to 46-fold, while this is only 2-3 fold in adult rats38. This 
phenomenon can be explained by an opposite developmental change in the 
activities of NAT and NAPE-PLD: while NAT activity decreases during development, 
in adult age NAPE-PLD is more active36. 
Finally, we have recently developed a new method for the detection of low intensity 
lipid signals in complex tissue samples13. It consists in a combination of liquid 
chromatography/mass spectrometry and ion mobility mass spectrometry. This 
methodology lead us to observe that particular species of NAPEs are increased 
following the administration of the Parkinson’s disease inducer 6-hydroxydopamine, 
in the Caudate Putamen of mice13. Even in this case, the increase in NAPE 
production was limited at the area of toxin administration, suggesting that these lipid 
molecules may be strictly related to the neurodegenerative process. 
2. PARKINSON’S DISEASE 
In his 1817 “An essay on the shaking palsy”, James Parkinson first described 
the clinical syndrome that was later to bear his name42. Charcot, later in the 19th 
century, gave credit to Parkinson by referring to this disease as “maladie de 
Parkinson” or Parkinson’s Disease (PD). More than 100 years passed (1925) before 
the neuropathological hallmarks underlying the clinical phenotypes were elucidated 
as the loss of dopaminergic neurons in the substantia nigra, together with the 
presence of intraneuronal inclusions termed Lewy bodies. 140 years after the 
original description by Parkinson (1957), dopamine was discovered as a putative 
neurotransmitter by Carlsson and colleagues43. The subsequent discovery by 
Ehringer and Hornykiewicz in 1960 that dopamine concentrations are remarkably 
decreased in the striatum of patients with PD paved the way for the first trials of 
levodopa in PD patients the following year and subsequent award of the Nobel Prize 
in Medicine to Carlsson (Kandel and Greengard) in 200044.  
PD is a chronic progressive neurodegenerative disorder characterized by the 
presence of motor symptomatology (bradykinesia, rigidity, rest tremor and postural 
disturbances)45, accompanied by an assortment of non-motor symptoms such as 
hyposmia, sleep behavior disorder, rapid eye movements, pain, personality 
changes, paresthesias and depression, that may even manifest before the motor 
symptoms.  
The prevalence of PD in industrialized countries is estimated at 0.3% of the entire 
population and about 1% in people over 60 years of age46. Reported standardized 
incidence rates of PD are 14 per 100,000 people in the total population, and 160 per 
100,000 people aged 65 years or older46. PD usually initiates in the fifth or sixth 
decade of life, but a small number of patients develop the disease at early age. PD 
is primarily sporadic, meaning that it arises in the absence of any obvious genetic 
linkage. However, in rare instances, PD is inherited and the phenotype is 
transmitted either as a recessive or dominant trait47. Yet the motor phenotypes of 
both the sporadic and familial forms of PD are almost identical, implying that they 
might share common underlying mechanisms. 
The pathological hallmarks of PD are the loss of the nigrostriatal dopaminergic 
neurons and the presence of intraneuronal proteinaceous cytoplasmic inclusions 
termed Lewy Bodies, accompanied by microgliosis. Lewy bodies are mainly 
composed by -synuclein and other misfolded proteins. The cell bodies of 
nigrostriatal neurons are located in the substantia nigra pars compacta (SNpc) and 
they project primarily to the caudate putamen (CPu). The SNpc neurons form the 
nigrostriatal dopaminergic circuit, which controls voluntary movements via the 
release of dopamine by these cells. Depletion of dopamine is most pronounced in 
the dorsolateral putamen, the main site of projection for these neurons. At the onset 
of the symptoms, putamenal dopamine is depleted 80%, and 60% of SNpc 
dopaminergic neurons have already been lost. The fact that the degree of terminal 
loss in the striatum is more conspicuous than the SNpc dopaminergic neuron loss, 
suggests that striatal dopaminergic nerve terminals are the primary target of the 
degenerative process and that neuronal death in PD may result from a “dying back” 
process47. The consequence of this denervation process is an imbalance in the 
striato-pallidal and pallido-thalamic output pathways, leading to an impairment in the 
initiation and the execution of movement (Fig. 4). 
 Figure 4: Classical model of the basal ganglia changes that underlie Parkinson’s Disease. a) 
Interconnections in the healthy condition. Dopaminergic input from the nigrostriatal pathway (1) 
synapses act on the striatal output neurons that mediate the indirect and direct GABA (gamma-
aminobutyric acid)-ergic output pathways. The indirect pathway (2) has inhibitory D2 dopaminergic 
receptors on its cell bodies, whereas the direct output pathway (3) has excitatory D1 dopaminergic 
receptors on its surface. The indirect (inhibitory) output pathway projects to the external globus pallidus 
(GPe), where it synapses on to the GABAergic pathway that projects to the subthalamic nucleus 
(STN). The glutamatergic neurons of the STN project to the internal globus pallidus (GPi), where they 
synapse on to GABAergic output to the thalamus. The direct (excitatory) output pathway projects to the 
GPi, where it synapses on to GABAergic output to the thalamus. Another input to the striatum comes 
from the frontal cortex (4). b) According to classical thinking about Parkinson's disease, loss of 
dopaminergic input from the substantia nigra leads to overactivity of the indirect (inhibitory) output 
pathway and underactivity of the direct (excitatory) output pathway. The number of dendritic spines on 
medium spiny neurons in the striatum is reduced. Cortical glutamatergic input to the striatum is also 
altered. 
PD is considered a multi-factorial disorder with both genetic defects and 
environmental factors influencing disease progression. Only 10% of all cases are 
linked to a genetic cause. To date 16 PARK loci have been reported, with synuclein-
α (SNCA, PARK1/4), LRRK2 (PARK8), parkin (PARK2) and PINK1 (PARK6) as the 
most common causes of familial PD. In addition, mutation in SNCA, LRRK2 and 
parkin have also been reported in sporadic PD48. Animal models of the disease 
support a critical interaction between genetics and the environment in PD 
pathogenesis. Indeed, the alterations in protein processing, with -synuclein as the 
main culprit, and the mitochondrial dysfunction together with increased formation of 
reactive oxygen species, are a probable biological mechanism contributing to 
dopaminergic neuron loss49. A substantial body of evidence also suggests that, in 
addition to or intermingled with these mechanisms, neuroinflammation may 
contribute to neuronal damage50. All these mechanisms are present both in familial 
and in sporadic PD, supporting a multi-factorial etiology. 
To date no therapies have been developed to cure PD: current treatments are 
symptomatic, but they do not stop the neurodegenerative process. The gold 
standard treatment is the administration of the dopamine precursor L-DOPA, 
dopamine agonist and/or dopamine degradation blockers. However the relief 
provided by this therapy is impaired in the long-term by loss of efficacy and the 
appearance of dose-dependent side effects: L-DOPA-induced dyskinesia and motor 
fluctuations51. Since the middle of the 1990s, deep brain stimulation has become a 
successful and frequently practiced neurosurgical approach for alleviating PD motor 
symptoms, in particular, stimulation of the subthalamic nucleus at high frequency. 
However, the fact that a pharmacotherapy first used in 1960s remains the front-line 
treatment choice for PD, underscores our lack of knowledge about the causes of 
neuronal degeneration in this disease. 
2.1 Molecular pathogenesis of Parkinson’s disease 
Whatever insult initially raises neurodegeneration, studies on toxic and 
genetic PD models proposed several pathogenic processes that might contribute to 
dopaminergic neuron loss in PD (Fig. 5). They include oxidative stress, 
mitochondrial dysfunction, impaired of calcium homeostasis, altered endoplasmic 
reticulum to Golgi trafficking, and altered mitophagy and proteasome function, 
among others. These factors are not mutually exclusive.  
The earliest hypothesis of PD pathogenesis was based on the discovery that three 
different mitochondrial complex 1 inhibitors, MPTP, rotenone and paraquat can 
emulate parkinsonism, leading to a selective loss of dopaminergic neuron in vitro as 
well as in vivo47. Inhibition of complex 1 causes ATP depletion, leading to an 
impairment of all ATP-dependent cellular processes, and production of free radicals 
that cause oxidative stress. Mitochondrial defects and oxidative stress are strictly 
correlated. Indeed, every condition that impairs mitochondrial function enhances 
radical oxygen species (ROS) formation and vice versa. In particular, the SNpc is 
exposed to high rates of ROS generation, because of the great abundance of 
cytoplasmic dopamine, which is prone to autoxidation, accompanied by a high iron 
content typical of this nucleus52. These conditions create an adverse environment 
for mitochondria, whose density and mass are lower in SNpc neurons53. The 
massive oxidative catabolism of dopamine can impair mitochondrial respiration and 
membrane permeability. Moreover, dopamine can modify several chaperones 
involved in mitochondrial protein quality control54. Thus, dopamine may be pivotal in 
rendering SNpc dopaminergic neurons particularly vulnerable to oxidative attack.  
Further support for primary role of oxidative stress and mitochondrial dysfunction, 
has emerged from the study of genetics of PD: virtually all proteins involved in 
genetic PD are associated with mitochondria, although with different functional roles. 
For instance, LRRK2 and -synuclein have been found to be associated with the 
mitochondria outer membrane. DJ-1 (PARK7) is a cytosolic protein that acts as an 
oxidative stress sensor and translocates to mitochondria under oxidative conditions. 
PINK1 can localize to both mitochondria and cytoplasm. Parkin is an ubiquitin 
ligase, which can translocate to mitochondria after phosphorylation by PINK1, acting 
as a mitochondria quality control pathway55. 
Another player in the pathogenesis of PD is the abnormal accumulation and 
processing of mutant or damaged proteins. Under physiological conditions, 
abnormal or misfolded proteins are normally targeted via ubiquitination to the 
proteasome or directed to the autophagic-lysosomal pathway. PD pathology is 
characterized either by the production of mutated and possibly toxic protein 
conformations, resulting in intracellular aggregation, or by alteration of the 
processes that normally recognize and process misfolded proteins, with subsequent 
accumulation and aggregation of cytotoxic damaged proteins, determining neuronal 
death. 
-Synuclein is a synaptic vesicle protein located in the cytoplasm or within lipid 
membranes, implicated in neurotransmitter release, synaptic plasticity, vesicle 
turnover and endoplasmic reticulum trafficking56. This protein is often overexpressed 
and misfolded in PD, leading to accumulation and aggregation to form Lewy bodies 
in the cytosol. Moreover, aggregated -synuclein can inhibit proteasome function 
interfering with the ubiquitin-proteasome system57. At the same time, the presence 
of ROS would increase the amount of misfolded proteins, boosting the demand of 
the ubiquitin-proteasome system to remove them. 
The mitochondrial system and the ubiquitin-proteasome system (UPS) are 
interconnected: complex 1 inhibitors cause a reduction in proteasomal activity58, and 
conversely, proteasomal inhibitors can cause mitochondrial damage. There is also 
evidence for a relationship between mitochondrial dysfunction and protein 
aggregation: complex 1 inhibition and other forms of oxidative stress lead to -
synuclein aggregation59.  
A third, common feature of PD is endoplasmic reticulum (ER) stress. Recent reports 
place ER dysfunction as an early player of PD pathogenesis60. The homeostasis of 
the ER can be altered by diverse conditions including calcium depletion from its 
lumen, oxidative stress and mutation in proteins that traffic through the secretory 
pathway, among other events. All of these perturbations can result in disruptions of 
the folding process in the ER, leading to the accumulation of misfolded/unfolded 
proteins (ER stress). ER stress activates the unfolded proteins response (UPR), a 
complex signal-transduction pathway that mediates cellular adaptation to restore ER 
homeostasis. Under chronic ER stress the UPR triggers cell death by apoptosis, 
eliminating damaged cells. Moreover, ER stress, induced by alterations in calcium 
levels, or other factors, may feed-back to enhance -synuclein aggregation61, 
suggesting a vicious cycle between ER stress and -synuclein aggregation.  Thus, 
the ER may represent the possible site of formation and accumulation of -
synuclein neurotoxic species, which may sequester important ER chaperones, 
leading to impaired ER folding and chronic stress. Furthermore, impaired vesicle 
transport from the ER triggers the accumulation of immature proteins in this 
compartment, and ER-Golgi trafficking defects were also shown to affect 
mitochondrial functioning60. 
Finally, it is now well accepted that chronic neuroinflammation is a pathological 
feature of the Parkinson’s disease50. Inflammatory processes, which normally 
prompt tissue protection and repair, might become detrimental and amplify cell 
death in a stressed or intoxicated microenvironment, such as the PD brain. They 
may contribute to oxidative damage to the nigrostriatal system; this is related to the 
massive release of nitric oxide, and subsequent formation of reactive nitrogen 
species, due to activation of inducible nitric oxide synthase, which is a typical 
phenomenon associated with microglia activation62. However, neuroinflammation 
does not seem to be the primary cause of cell death, but rather, it may be a 
secondary event that perpetuates the vicious cycle of neurotoxicity63. 
 Figure 5: Molecular mechanism dysregulated in PD. Mitochondrial, proteasomal and autophagy 
dysfunction, protein aggregation, dopamine meabolism and oxidative stress, partecipate to determine 
dopaminergic neurons death. 
To summarize, there are multiple levels of intersection between these pathways 
(Fig. 5) rather than a minor abnormality in one or more cellular processes. Thus, the 
alteration of one pathway can be amplified by its interaction with other cellular 
processes to potentially result in several forms of stress that would ultimately force a 
cell into programmed cell death. Hence, many factors implicated in the pathogenesis 
of PD may converge to generate a proteotoxic insult to cells. 
2.2 Experimental models of Parkinson’s disease 
Animal models of PD can be classified in three main categories:  
1. “classic” models based on neurotoxins that selectively target 
catecholaminergic neurons (such as 6-hydroxydopamine, 1-methyl-1,2,3,6-
tetrahydropiridine, agricultural pesticides etc.); 
2. more recent models employing genetic manipulations that either introduce 
similar mutations to those find in familial cases of PD (-synuclein, DJ-1, 
Parkin etc.);  
3. genetic models that selectively disrupt nigrostriatal neurons (MitoPark, Pitx3, 
Nurr1, etc.).  
Each one of these models has its own advantages and limitations, thus some are 
better suited for studying PD pathogenesis, while others are more appropriate to test 
potential therapeutic treatments. None of the current available models phenocopy 
PD, mainly because they lack some specific neuropathological and/or behavioral 
feature of this disease47.  
The crucial requirement for an etiologic model of PD is the adult onset of relatively 
specific and progressive dopaminergic neuron degeneration. A behavioral correlate 
of the nigrostriatal dopaminergic pathway degeneration is also desirable, but rodents 
do not develop typical parkinsonism because motor system organization differs 
between rodents and humans. Thus, the value of a specific behavioral phenotype 
depends upon its relationship to striatal dopaminergic function rather than apparent 
similarity to a symptom of PD. The formation of Lewy bodies is also a desirable but 
not essential feature. Lewy bodies are not a specific characteristic of PD, indeed, 
they are not found in a minority of clinically defined PD cases, such as parkin-related 
PD.  
It is important not just using any model but in selecting the optimal model whose 
strengths are appropriate for investigating the question being asked and whose 
weaknesses will not invalidate the interpretation of an experiment.   
2.2.1 Gene-based models 
The rationale for investigating rare genetic forms of a common sporadic 
illness is the expectation of a phenotypic similarity between the genetic and sporadic 
forms of the disease, indicating common pathogenic mechanisms and, help in the 
research on a key biochemical pathway.  
The most common genetic PD models are SNCA (-synuclein, PARK1 and 4), 
parkin (RBR E3 ubiquitin protein ligase, PARK2), PINK1 (PTEN-induced putative 
kinase 1, PARK6), DJ-1 (PARK7) and LRRK2 (leucine-rich repeat kinase 2, 
PARK8). All these models show little or no nigrostriatal degeneration, striatal 
dopamine depletion and motor symptoms. Only some of these models develop -
synuclein aggregates in the SNpc and other brain regions. In general, these models 
offer the possibility to study the pathology and pathogenesis of PD, and to better 
understand the role of these proteins in both physiological and pathological states. 
Inactivation of multiple PD genes is insufficient to cause significant nigral 
degeneration. Thus, other approaches have been used to create new models, 
based on the deletion of transcription factors necessary for the development and 
survival of dopaminergic neurons, such as sonic hedgehog (SHH), pituitary 
homeobox 3 (Pitx3), nuclear receptor related protein-1 (Nurr1), engrailed 1 (EN1). 
These mice showed loss of dopaminergic neurons without Lewy bodies formation 
and altered locomotor activity. The “MitoPark” model is based on the inactivation of 
a mitochondrial transcription factor selectively in dopaminergic neurons, resulting in 
a parkinsonism phenotype that includes an adult-onset, slowly progressive 
impairment of motor function, dopaminergic neuron death, intraneuronal inclusions 
and degeneration of nigrostriatal pathways64. Overall, these models can be 
appropriate for addressing neuroprotection65. 
2.2.2 Toxin-based models 
Neurotoxin-based models can induce massive degeneration of the 
nigrostriatal pathway that produces strong motor symptoms. These models have 
been widely used to elucidate the neurodegenerative process of SNpc dopaminergic 
neurons and to test symptomatic treatments. Among the neurotoxins used to cause 
dopaminergic neurodegeneration, 1-methyl 4-phenyl 1,2,3,6-tetrahydro-pyridine 
(MPTP), 6-hydroxydopamine (6-OHDA), and more recently rotenone, paraquat and 
maneb have received attention.  
- The neurotoxic power of MPTP was discovered in 1982, when young drug-
addicted Californians injected with synthetic heroin accidentally 
contaminated with MPTP, and suddenly developed parkinsonian symptoms. 
In humans, monkeys and mice, MPTP produces an irreversible and severe 
parkinsonian syndrome. A weakness of this model is the lack of Lewy 
bodies. Indeed, only MPTP-injected monkeys have intraneuronal inclusions, 
reminiscent of Lewy bodies.  
After systemic administration, MPTP, which is highly lipophilic, crosses the 
blood-brain barrier within minutes. Once in the brain, the pro-toxin MPTP is 
oxidized to 1-methyl-4-phenyl-2,3-dihydropyridinium (MPDP+) by 
monoamine oxidase B in glia and serotoninergic neurons, the only cells that 
contain this enzyme. It is then transformed to MPP+ (probably by 
spontaneous oxidation), the active toxic molecule, and released into the 
extracellular space. MPP+ is a high-affinity substrate for the DAT, as well as 
for norepinephrine and serotonin transporters66. Once inside neurons, MPP+ 
accumulates in the cytoplasm and into synaptic vesicles. MPP+ also enters 
the mitochondria and impairs oxidative phosphorylation by blocking the 
multienzyme complex I of the mitochondrial electron transport chain67. This 
blockade rapidly leads to decreases in tissue ATP content, leading to the up-
regulation of the apoptosis regulator Bax and the kinase JNK, accompanied 
by the release of cytochrome c and the activation of caspase-3 and 9, as well 
as NMDA receptor-mediated excitotoxicity and neuroinflammatory 
processes68. Furthermore, by hindering the flow of electrons through 
complex I, MPP+ can stimulate the production of ROS, especially 
superoxide.  
- Rotenone is a widely used herbicide, pesticide and piscicide. Interestingly, it 
reproduces almost all PD hallmarks. Indeed, the administration of low-dose 
intravenous rotenone to rats induces SNpc dopaminergic neuron loss, 
nigrostriatal dopaminergic denervation, behavioral alterations, inflammation, 
Lewy bodies-like inclusions containing -synuclein and ubiquitin, oxidative 
stress and gastro-intestinal problems69. 
Highly lipophilic, rotenone easily crosses the blood brain barrier and enters 
all cells without being dependent on a specific transporter. Its mechanism of 
action includes binding and inhibition of mitochondrial complex I (at the same 
site as MPP+), with subsequent production of intracellular ROS. It is also 
able to block proteasome activity and decrease dopamine and GSH levels, 
resulting in oxidative damage.  
- Paraquat (N,N’-dimethyl-4-4’-bipyridinium), a widely used pesticide and 
herbicide was identified as an environmental contaminant with a molecular 
similarity to MPP+. Exposure to paraquat may confer an increased risk for 
PD. Indeed, systemic chronic administration of paraquat to mice leads to a 
slowly progressive SNpc dopaminergic neuron degeneration accompanied 
by -synuclein containing inclusions59.   
Paraquat does not easily penetrate the blood brain barrier70 and it is not a 
good substrate for the dopamine transporter. Toxicity induced by paraquat is 
primarily mediated by redox cycling with cellular diaphorases such as 
NADPH oxidase and nitric oxide synthase, stimulating the generation of 
superoxide71. In addition, the action of this toxin seems to induce the 
sequential phosphorylation of JNK and c-Jun, and the activation of caspase-
3, leading to apoptosis68.  
- Maneb has been shown to potentiate the effects of both MPTP72 and 
paraquat. One of the advantages of using paraquat and/or maneb model 
relies on their ability to induce the expression of Lewy bodies-like inclusions 
containing -synuclein59. 
- 6-hydroxydopamine will be discussed in the next paragraph. 
 Figure 6: Pathogenesis of toxin‐induced models. MPTP crosses the blood‐brain barrier and is 
metabolized to 1‐methyl‐4‐phenylpyridinium (MPP+), the active toxic compound, by the enzyme 
monoamine oxidase B (MAO‐B). MPP+ is then internalized by dopamine transporter and enters 
dopaminergic cells, where it impairs mitochondrial respiration by inhibiting complex I of the electron 
transport chain, leading to oxidative stress and activation of programmed cell death pathways. Both 
paraquat and 6‐hydroxydopamine (6‐OHDA) easily cross cell membrane through the dopamine 
transporter and exert their toxicities, in part, by damaging mitochondria with the subsequent production 
of ROS and quinones causing the degeneration of the nigrostriatal dopaminergic neurons. Rotenone is 
extremely hydrophobic and penetrates easily the blood brain barrier and cellular membrane inducing 
the formation of α‐synuclein aggregates and mitochondrial impairment followed by ROS and quinones 
production. 
2.2.3 6-Hydroxydopamine 
6-Hydroxydopamine (6-OHDA), the first neurotoxin associated with SNpc 
dopaminergic neuronal death, was introduced in PD research almost 50 years 
ago73. 6-OHDA induced-toxicity is relatively selective for monoaminergic neurons, 
resulting from preferential uptake by dopaminergic and noradrenergic transporters. 
The neurotoxicity of 6-OHDA is mainly imputed to its ability to form ROS that may 
arise from two distinct mechanisms: deamination by monoamine oxidase or auto-
oxidation. 
Indeed, 6-OHDA, like DA, is a substrate for monoamine oxidase (MAO) and this 
enzymatic reaction produces hydrogen peroxide. Accordingly, selegiline, a MAO 
inhibitor, prevents 6-OHDA toxicity. However, several lines of evidence suggest that 
under physiological conditions, 6-OHDA undergoes a rapid and nonenzymatic auto-
oxidation74, shown to generate several toxic species including quinones, hydrogen 
peroxide, superoxide radicals, and the highly reactive hydroxyl radical. The 
formation of ROS generated either by MAO or autoxidation may be amplified by iron 
that catalyzes a Fenton reaction. Indeed, iron levels are elevated in SNpc and 
striatum after 6-hydroxydopamine injection. The participation of iron in 6-OHDA 
toxicity is also suggested by studies showing that 6-OHDA-induced neurotoxicity is 
prevented by iron chelating agents75 and that direct administration of iron into the 
SNpc produces similar neurotoxic effects.  
Oxidative stress impairs intracellular redox potential regulation and causes lipid 
peroxidation accompanied by DNA strand break, mutations, impairment of glucose 
uptake and a disorganization of the cytoskeleton. 6-OHDA can also impair 
mitochondrial function by various mechanisms: first of all, it interacts with and 
inhibits complex I in isolated brain mitochondria76, independently from ROS 
formation. Moreover, 6-OHDA stimulates a ROS-related collapse in mitochondrial 
membrane potential and is a strong uncoupler of oxidative phosphorylation. As a 
result of these toxic events, both necrotic and apoptotic mechanism of cell death 
occur in response to 6-OHDA77. 
Because 6-OHDA cannot cross the blood brain barrier, it must be administered by 
local stereotaxic injection into the SNpc, median forebrain bundle (MFB) or striatum, 
destroying nigral dopaminergic neurons and depleting the pool of dopamine in the 
striatum. 
Although generally nerve terminals are more sensitive to 6-OHDA toxicity than 
axons and cell bodies, when injected into the SNpc or in the MFB, 6-OHDA 
produces a massive (>90%) and extremely rapid lesion in the nigrostriatal 
pathway78. Indeed, substantia nigra injections induce degeneration of dopaminergic 
neurons within 12 hours, preceding a significant loss of striatal terminals, that occurs 
2-3 days later78. The injection in the MFB, induces degeneration in striatal terminals 
before dopaminergic cell death occurs79. 
In contrast to the nigra and MFB, when delivered into the striatum, 6-OHDA induces 
slow, progressive and partial damage to the nigrostriatal structure (60%) in a 
retrograde fashion over a period of up to 3 weeks80. In particular, following striatal 
administration of 6-OHDA, the loss of dopaminergic fibers in the striatum begin 
immediately and is very rapid: one day after 6-OHDA administration, 60% of 
dopaminergic fibers are already degenerated, remaining stable later on. Despite the 
rapid loss of axonal fibers in the caudate, changes in the SNpc neurons are not 
immediately appreciable. Indeed, alterations in cell size, dendrite length and gene 
expression require several days, and the reduction in the number of dopaminergic 
cells is not significant until 6-9 days post-surgery. The apoptotic cascade is activated 
from 9 days post-lesion and condensed chromatin is observed in dying 
dopaminergic neurons at 12 days post-surgery. Moreover, ROS are highly diffusible 
through biological membranes and suitable for cellular signaling, recruiting microglial 
cells and astrocytes. 6-OHDA induces a pronounced progressive microgliosis and 
astrogliosis in the caudate at early stages post-lesion; on the other hand, in the 
SNpc the activation and proliferation of microglia and astrocytes does not occur until 
6-9 days post-surgery, with a slight advance of microgliosis81. 
For striatal stereotaxic lesions, 6-OHDA is generally injected unilaterally for two 
main reasons: first of all, each animal can serve as its own control, with a lesioned 
and unlesioned hemisphere; second, bilateral lesions are reported to cause aphagia 
and adipsia. However, the major advantage of using the 6-OHDA model is its rather 
unique effect on quantifiable circling motor abnormality in animals82: subsequent to 
the unilateral lesioning, systemic administration of dopamine receptor agonists, or 
dopamine releasing compounds induces asymmetrical rotation82. Importantly, 
magnitude of nigrostriatal lesions correlates with the circling motor behavior80,82.  
Bilateral lesions in the CPu would probably serve as a closer parallel to the human 
disease than unilateral lesions because both striata are affected in human PD. 
However, a notable advantage of this model is the ability to assess the anti-PD 
properties of new drugs and the benefit of transplantation or gene therapy to repair 
the damaged pathways. Furthermore, the fact that the administration of 6-OHDA in 
the striatum leads to a gradual loss of dopaminergic neurons, gives the opportunity 
to study early phases of the pathology and use this therapeutic window to 
investigate potential neuroprotective effectors. On the other hand, 6-OHDA model 
lacks the progressive age dependent effects of PD and do not show formation of 
Lewy bodies. 
2.2.4 Basic assessments of the nigrostriatal dopaminergic structure 
and function  
To evaluate neurodegeneration or neuroprotection using neurotoxic models, 
the most common assessment is to analyze the integrity and function of the 
nigrostriatal pathway. For this purpose, some specific techniques have been 
developed over the years. In the chapter below, I will summarize the most used 
techniques and the ones I used during my work. 
Quantification of dopaminergic neurons in the SNpc: in the mesencephalon, 
there are three groups of dopaminergic neurons classified historically as A8, A9 and 
A10. The A8 group is located in the retrorubral area, whereas the A9 and A10 
groups belong to the substantia nigra and ventral tegmental area, respectively. The 
distribution of dopaminergic neurons in the nigra is not homogeneous. Thus, when 
the nigra is sectioned coronally, there is a great difference in the density of 
dopaminergic neurons between the caudal and the rostral regions. It is necessary, 
therefore, to sample the population of dopaminergic neurons at different levels 
throughout the entire SNpc. One way to sample the entire area efficiently is to count 
dopaminergic neurons systematically at a regular section interval. For this purpose, 
the gold standard is to use an unbiased stereological cell counting with optical 
dissector system83. Major components required for this method are computerized 
stereology software and a microscope with a motorized stage.   
Quantification of dopaminergic terminals in the striatum: the projection of fibers 
to the striatum from the nigral dopaminergic neurons has been well established84. 
Although the density of striatal dopaminergic terminals frequently correlates with 
number of their cell bodies in the SNpc, it is not uncommon to observe differential 
damage or protection between these two structures. Indeed, striatal fibers are more 
sensitive to 6-OHDA toxicity than cell bodies and the quantification of striatal 
dopaminergic terminals is also informative of neurodegeneration. The density of 
striatal dopaminergic terminals can be digitized and then quantified based on optical 
density of fiber density of tyrosine hydroxylase immunoreactivity. As an alternative to 
immunostaining, fresh striatal tissue can be isolated for immunoblotting using 
tyrosine hydroxylase or dopamine transporter as markers to assess the entity of the 
lesion83. 
Quantification of dopamine content in the striatum: in addition to structural 
analysis, it is also important to assess the function of the nigrostriatal pathway. A 
common way to measure dopamine is to use reverse-phase high-performance liquid 
chromatography (HPLC) coupled with electrochemical detecting83.  
Assessment of motor function: many behavioral tests are designed to assess 
motor phenotypes linked to the nigrostriatal function such as locomotor activity, 
rotation, rotarod, stride length of the paws, cylinder test and pole test85.  
In many cases, animals with unilateral lesion present characteristic features when 
given a choice: they (I) spontaneously prefer food presented from ipsilateral side, (II) 
show more foot-slips and falls when traversing narrow beam or grids, (III) show 
reduced use of the contralateral paw for stabilization and balance when rearing, (IV) 
are much more likely to turn in the ipsilateral direction when confronting an obstacle, 
and (V) show impaired stepping and placing reflexes when moved into whisker or 
paw contact with surfaces or edges. Many of these aspects have been formalized 
into standardized tests such as the cylinder and footprint tests. 
1. LOCOMOTOR ACTIVITY: animal’s movements around an open arena are 
observed and recorded. When placed in the center of a field, a mouse will 
typically run to the perimeter and then explore the whole arena remaining 
close to the wall (thigmotaxis). Over time, as the animal habituates to the 
environment, it will increase its movement through the central area before 
going back to the perimeter. This behavioral profile is the basis of the study 
of the open-field locomotor activity. Unfortunately, in rodents the motor 
component in this test is typically confounded by anxiety levels. 
2. ROTATION TEST: this test has been used for decades to assess the motor 
asymmetry in the unilateral 6-OHDA injection86. Indeed, following unilateral 
dopamine depletion, the contralateral dopaminergic pathway remains intact, 
and the animal exhibits a marked spontaneous postural bias to the side of 
the lesion; this can be amplified and transformed by pharmacological 
activation into a head-to-tail turning response. Stimulation of dopamine 
release from intact terminals by indirect agonists (such as amphetamine) 
enhances the spontaneous bias, causing ipsilateral rotations, whereas 
activation of supersensitive receptors on the denervated side by a direct 
agonist (for example apomorphine) drives vigorous contralateral rotation. 
The rate of rotation is easily quantified using an automated rotometer test 
apparatus. 
3. ROTAROD: this test measures body coordination and balance. Briefly, a 
mouse is placed on a rod that can rotate at fixed or accelerating speed. The 
length of time the animal can maintain balance and keep walking on the 
rotating rod is recorded. Mice are tested on separate trials at a series of fixed 
speeds, or into a single trial by an accelerate version of the test. The 
accelerating test is quicker and more efficient, but it confounds motor 
coordination at different speeds with fatigue, whereas the fixed-speeds test 
provides separate data on each range of rotation speeds and is probably 
more sensitive. 
4. FOOTPRINT TEST: this test is a valid way to measure abnormal movement, 
analogous to the shuffling gait in PD patients, and can be used to measure 
the stride length of the paws. Briefly, the fore and hind limbs of the mice are 
painted with different colors and the mouse is encouraged to walk in a 
narrow corridor over absorbent paper. The footprint patterns are then 
analyzed for a range of measurements, including stride length, base width, 
overlap between fore and hind paws and paw and finger splay. 
5. CYLINDER TEST: is a simple and efficient test of unilateral deficiency in 
voluntary forelimb use85. Mice are placed in a glass cylinder and filmed: mice 
with unilateral 6-OHDA lesions exhibit a reduction in the use of the 
contralateral paw when rearing to explore the environment. Paw usage can 
be determined by measuring the number of impaired forelimb wall contacts 
made with the contralateral paw, as a percentage of total contacts86. 
6. POLE TEST: it is another way to assess body coordination and balance. The 
mouse is placed facing upward on top of a vertical made of wood or wire-
mesh. A normal mouse would grip the pole before turning through 180° and 
slowly climbing down to the base. The time that the animal takes to orient 
downward and the total time spent to descend to the base of the pole is 
recorded. Abnormalities in response can include climbing, falling or slipping 
down backwards87. 
2.2.5 Cellular models of Parkinson’s disease  
Most new experimental therapeutic strategies for PD are now first evaluated 
using simpler models that are easier to get than the animals. This approach leads to 
a reduction of the number of animal experiments needed, and permits to deeply 
study the molecular mechanism underling the pathology with simpler techniques. 
The most used models consist in the use of cells cultures or organotypic cultures. 
Organotypic cultures represent a recently developed technique based on the culture 
of parts or the whole organ. This approach combine features of cell culture and 
intact animals: neurons are more easily accessible for pharmacology, gene transfer 
and repeated imaging than inside the animal. At the same time, organotypic cultures 
avoid the deprivation of neurons natural environment, maintaining afferent and 
efferent connections. Usually, brain slices from post-natal rat or mouse pups are 
used, cultured either on coverslips or on membranes at the interface between 
medium and the air of the incubator88. 
On the other hand, cell cultures can be classified in two subgroups: primary cultures 
of neurons and immortalized cell lines. 
The most prominent advantages of cell cultures are the easy access to genetic and 
pharmacological interventions, other than for imaging studies and various 
biochemical assays. Moreover, the use of cells gives the possibility to implement 
high-throughput screening for drug candidates. Obviously, primary cell cultures are 
physiologically more relevant than immortalized cell lines, but they are difficult to 
maintain and, depending on the age of the source animals or the dissection 
accuracy, can introduce experimental variability. 
Primary cultures of neurons from SNpc of patients and controls may be considered 
the most reliable models to unravel the molecular mechanisms underlying this 
disease. However, the inaccessibility and lack of proliferation of such neurons 
largely precludes their use. 
Alternatively, primary mesencephalic cultures are typically prepared from mouse or 
rat embryos. They contain midbrain dopaminergic neurons cultured in the context of 
their physiological neighbors. As other neuronal cultures, neurons readily 
differentiate and form neurites and synapses. Even though these cultures are often 
referred to as primary dopaminergic neurons, TH positive neurons actually represent 
only 5-10% of the total population. This fact constitutes an invincible obstacle 
because significant changes that may occur in dopaminergic neurons are diluted or 
cancelled by changes in non-dopaminergic neurons. Moreover, there is more 
variability between cultures prepared on different days and gene transfer is more 
difficult than in immortalized cell lines89.  
An emerging new category of cell models of PD is represented by patient-derived 
induced pluripotent stem cells (iPSC) that can be differentiated into dopaminergic 
neurons (and other relevant cell types such as glia cells)90. 
Immortalized cell lines include: 
- non-neuronal tumor cell lines such as pheochromocytoma (PC12) cells77; 
- neuronal human tumor cell lines (SH-SY5Y)91; 
- mouse neuroblastoma cell lines (Neuro-2a); 
- cells hybrids obtained by the fusion of mice embryonic ventral 
mesencephalic and neuroblastoma cells (MN9D). 
They all represent homogenous populations of continuously proliferating cells; this 
allows large-scale experiments with reproducible results in a variety of tests. 
Moreover, all these cells mimic many aspects of the dopaminergic neuron death 
observed in PD when treated by neurotoxins such as MPP+, 6-OHDA or rotenone. 
In the present chapter, I will explore more in deep SH-SY5Y cells biology, the 
cellular model I used during my work. 
The neuroblastoma SH-SY5Y cell line provides an unlimited supply of cells of 
human origin with the similar biochemical characteristics of human dopaminergic 
neurons. SH-SY5Y cells are a thrice cloned subline of SK-N-SH cells which were 
originally established from a bone marrow biopsy of a neuroblastoma patient with 
sympathetic adrenergic ganglial origin in the early 1970s. This cell line has been 
widely used as a model of neurons, because they show many biochemical and 
functional properties of neurons. Indeed, the initial characterization of the SH-SY5Y 
cell line showed moderate activity of dopamine--hydroxylases and negligible levels 
of choline acetyl-transferase, acetylcholinesterase and butyryl-cholinesterase, basal 
noradrenaline release and tyrosine hydroxylase activity. Tyrosine hydroxylase is the 
rate-limiting enzyme of the catecholamine synthesis pathway and converts tyrosine 
to L-dopa, the precursor of dopamine, which is converted to noradrenaline by 
dopamine--hydroxylase. Furthermore, SH-SY5Y cells express dopamine 
transporter (DAT), a protein expressed only in dopaminergic neurons within the 
central neuron system, that is a prerequisite for MPP+ and 6-OHDA incorporation 
into neurons. This is the reason why the SH-SY5Y cell line has been widely utilized 
to study mechanisms of neurotoxin action.  
Apart from the dopaminergic phenotype, the ability of the selected cell line to 
reproduce the cellular abnormalities of PD is crucial for the validity of the model. 
One of the main hallmarks of PD is -synuclein aggregation. To mimic this 
pathological feature, overexpression of WT -synuclein or stable expression of one 
of its familial mutations has been successfully used in SH-SY5Y cells92. 
Furthermore, spontaneous -synuclein aggregation has been reported in non-
transfected SH-SY5Y cells93and this cell line is  sensitive to extracellular -
synuclein-induced toxicity. Other PD-related problems, such as abnormal 
mitochondrial function, oxidative stress and autophagy or proteasomal dysfunction, 
have been reproduced in SH-SY5Y cells as well. These hallmarks can be triggered 
by the administration of specific drugs or, alternatively, by the knockdown of a gene 
corresponding to a familial PD-gene or expression of a familial PD-gene. 
As this cell line is derived from immature neoplastic neural crest cells that exhibit 
properties of stem cells, SH-SY5Y cells are induced to differentiate upon treatment 
with a variety of agents, among all retinoic acid94 or brain derived neurotrophic 
factor95. The SH-SY5Y cells can be differentiated in a more pronounced 
dopaminergic phenotype, however, some agents that induce differentiation also 
confer tolerance to SH-SY5Y cells, thus the role of toxicity or protection cannot be 
evaluated in these cells91. On the other hand, use of undifferentiated SH-SY5Y cells 
has some disadvantages. First, the number of cells increases during the experiment, 
so it is difficult to distinguish if an agent influence the proliferation rate or the rate of 
cell death; second, SH-SY5Y cells in culture are unsynchronized and do not always 
express the typical markers of mature neurons. However, both undifferentiated and 
differentiated SH-SY5Y cells have gained broad acceptance as models of 
dopaminergic neurons, and they have been widely used as a PD cell model, even 
though both models show weaknesses. 
To summarize, there are many other types of model besides the use of the animal, 
everyone has its advantages and weakness. It is important even in this case, to 
understand which is the best model to use, considering the aim of the study. 
  
AIM OF THIS WORK 
Parkinson’s disease represents a huge burden for public health, with a 
predicted prevalence rate of 9 million people worldwide by 2030. Unfortunately, the 
etiology of neurodegenerative condition, is still poorly understood. Consequently, no 
therapy able to revert the pathology has been developed. Thus, there is the need to 
clarify molecular pathways that are involved in the neurodegenerative disease, to 
further develop new therapies to cure or prevent the progression of the pathology to 
late stage. 
It is known that NAPEs are produced in large quantities in the injured brain.  
The aim of the present work was to understand whether and how this process is 
involved in PD neurodegeneration.  
To address these questions, I used a multidisciplinary approach, combining 
lipidomics, molecular and pharmacological techniques, using both in vitro and in vivo 
models of Parkinson’s Disease.   
  
MATERIALS AND METHODS 
Chemicals 
6-hydroxydopamine (6-OHDA) was purchased from Sigma Aldrich (Milan, Italy); 
solutions were prepared immediately before use in a vehicle consisting of 0.2% 
ascorbic acid in saline (0,9% NaCl). 
ARN19874 was synthesized in our laboratory, the solution was freshly prepared in 
DMSO and used at a concentration of 50 μM. 
Analytical grade standards of dopamine, serotonin, homovanillic acid (HVA) and 3, 
4-dihydroxyphenylacetic acid (DOPAC) were purchased from Sigma Aldrich (Milan, 
Italy). NAPE standards and internal standards were synthetized in our laboratory as 
previous described13.  
Cells 
SH-SY5Y cells were purchased from Sigma Aldrich (Milan, Italy) and cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM) (Euroclone, Milan, Italy) 
supplemented with 10% fetal bovine serum (FBS, Gibco, Thermo Fisher Scientific, 
Waltham, MA, USA), 2mM L-glutamine and antibiotics (Euroclone, Milan, Italy) at 
37°C and 5% CO2. Cells were treated with 100 μM 6-OHDA or vehicle (0.2% 
ascorbic acid saline) added to the culture medium, and analyzed at different time-
points (2, 4, 6 and 8 h) post treatment. ARN19874 was administered to cells 2 h 
prior to 6-OHDA/vehicle, cells were then harvested and analyzed 8 hr post 6-OHDA 
administration. 
Animals 
C57BL/6J NAPE-PLD-/-  mice were generated as described previously28. They were 
housed in a temperature and humidity controlled room under a 12 h light/dark cycle 
with water and food ad libitum. All procedures were performed in accordance with 
the Italian regulations on the protection of animals used for experimental and other 
scientific purposes (D.M. 116192), and European Union regulations (O.J. of E.C. L 
358/1 12/18/1986). Mice were anesthetized with ketamine and xylazine (100 and 10 
mg/kg, respectively, i.p.), placed in a stereotaxic frame and unilaterally lesioned in 
the striatum by two intracerebral injections (coordinates of the first and second 
injection respectively: anterior-posterior: +1 / +0.3; medial-lateral: +2.1 / +2.3; 
dorsal-ventral: -2.9). A small hole was drilled in the exposed skull and a cannula of 
0.2 mm thickness (33 gauge) was used for administration of 6-OHDA (3.2 μg/μL; 1 
μL each, at a rate of 0.25 μL/min). The cannula was left in place for 2 min before 
being slowly removed. Mice were then sutured and allowed to recover in a heated 
recovery chamber. Mice were sacrificed at different time-points (48h and 3 weeks) 
post-surgery and caudate putamen and substantia nigra were collected, snap-frozen 
in liquid nitrogen and stored in -80°C until analysis. 
NAPE-PLD silencing and overexpression 
Silencing. siRNA experiments were performed using the NAPE-PLD gene-specific 
27mer siRNA duplex purchased from Origene Tecnologies (Rockville, MD, USA). 
siRNA duplex carrying TYE-563 fluorescence was used for transfection monitoring. 
siRNA duplex carrying a 27-mer sequence targeting HPRT gene was used as 
positive control. Scrambled siRNA were included in  each experiment as control. 
NAPE-PLD siRNA complexes (10 nM) were formed by mixing siRNA with 
lipofectamine (Invitrogen, Thermo Fisher Scientific) for 10 min at room temperature 
and then added to SH-SY5Y cells cultured with 1% FBS Optimem medium (Gibco, 
Thermo Fisher Scientific). After 6 h, the medium was changed to fresh full growth 
medium, cells were further incubated for 18 h, then treated with 6-OHDA.  
Overexpression. NAPE-PLD sequence was amplified from NAPE-PLD variant 2 
cDNA (Openbiosystem, clone ID: 4375696) using the following primer pair: forward 
5’-CGGGGTACCATGGATGAAAATGAAAGCAACC, and reverse 5’-
ATAAGAATGCGGCCGCTTAAAAGTTTTCATCATCATTATTTAGG.  The obtained 
sequence was cloned in the mammalian expression vector pCDNA3.1 (Life 
Technologies), using KpnI and NotI restriction enzymes. SH-SY5Y cells (1 x 106 
cells/ plate) were transfected with NAPE-PLD construct using Jet Prime reagent 
(Polyplus transfectionTM, Illkrch, FR) following manufacturer’s instructions. Briefly, 
plasmid (2 μg) was mixed with Jet Prime reagent (10 μL) and Jet Prime buffer (100 
μL) for 15 min at room temperature and then added to the medium of SH-SY5Y 
cells. 24 h after transfection, cells were either analyzed for NAPE-PLD expression or 
treated with 6-OHDA.  
Cell viability 
To determine cell viability, SH-SY5Y cells were counted using a ScepterTM cell 
counter (Merck Millipore, Darmstadt, DE). At the end of 6-OHDA incubation, the 
cells were harvested, diluted in PBS and counted. Cells with the same morphology 
and size were considered. 
RNA isolation, cDNA synthesis and real time quantitative PCR  
Total RNA was prepared using the Ambion purelink RNA mini-kit as directed by the 
supplier. Samples were treated with DNase to eliminate genomic DNA (PureLink 
DNase, LifeTecnologies, Milan, Italy) and cDNA synthesis was carried out with 
SuperScript VILO cDNA synthesis kit according to the protocol (LifeTecnologies) 
using 0.5-1µg of purified RNA. First-strand cDNA was amplified using the TaqMan 
Universal PCR Master Mix (LifeTechnologies) according to the manufacturer’s 
instructions. Probes were purchased from Thermo Fisher Scientific. Quantitative 
PCR was performed in a 96-well PCR plate and run at 95°C for 10 min followed by 
40 cycles, each cycle consisting of 15 sec at 95°C and 1 min at 60°C, using a ViiA7 
instrument (ViiA™ 7 Real-Time PCR System, LifeTechnologies). To determine the 
expression stability and the geometric mean of different housekeeping genes 
(GAPDH, HMBS, HPRT) a free-available and widely used software (Bestkeeper, 
http://www.gene-quantification.de/bestkeeper.html96) was used. ΔCt values were 
calculated by subtracting the Ct value of the geometric mean of housekeeping 
genes from the Ct value for the genes of interest. The relative quantity of genes of 
interest was calculated by the equation 2-ΔCt. Data are reported as fold induction 
over control. 
mRNA measurements by array 
Substantia nigra specimens from the contralateral or ipsilateral side of three wild 
type mice and three NAPE-PLD-/-  mice, were used for mRNA analysis. mRNA was 
extracted as reported above and cDNA synthesis was carried out with RT2 First 
Strand Kit (Qiagen, Milan, Italy), according to manufacturer’s instructions, using 0.25 
µg of purified mRNA. First-strand cDNA was then load on the RT2 Profiler PCR 
Array (Qiagen, Cod. 330231 PAMM-124ZA) and run at 95°C for 10 min followed by 
40 cycles, each cycle consisting of 15 sec at 95°C and 1 min at 60°C, using a ViiA7 
instrument (ViiA™ 7 Real-Time PCR System, LifeTechnologies). Data analysis was 
carried out with the SABiosciences PCR Array Data Analysis software 
(www.SABiosciences.com/pcrarraydataanalysis.php.), considering separately the 
two strain, with lesioned side versus control side. Genes analyzed are reported in 
Table 1. 
Table 1: RT2 Profiler PCR Array genes 
Position Symbol Description 
A01 Aldh1a1  Aldehyde dehydrogenase family 1, subfamily A1 
A02 Apc  Adenomatosis polyposis coli 
A03 App  Amyloid beta (A4) precursor protein 
A04 Atp2b2  ATPase, Ca++ transporting, plasma membrane 2 
A05 Atxn2  Ataxin 2 
A06 Atxn3  Ataxin 3 
A07 Basp1 Brain abundant, membrane attached signal protein 1 
A08 Bdnf  Brain derived neurotrophic factor 
A09 Cadps  Ca2+-dependent secretion activator 
A10 Casp1  Caspase 1 
A11 Casp3  Caspase 3 
A12 Casp7  Caspase 7 
B01 Casp8  Caspase 8 
B02 Casp9  Caspase 9 
B03 Cdc27  Cell division cycle 27 homolog (S. cerevisiae) 
B04 Cdc42  Cell division cycle 42 homolog (S. cerevisiae) 
B05 Cdh8  Cadherin 8 
B06 Chgb  Chromogranin B 
B07 Cul2  Cullin 2 
B08 Cxxc1  CXXC finger 1 (PHD domain) 
B09 Ddc  Dopa decarboxylase 
B10 Dlk1  Delta-like 1 homolog (Drosophila) 
B11 Drd2  Dopamine receptor D2 
B12 Egln1  EGL nine homolog 1 (C. elegans) 
C01 Fbxo9  F-box protein 9 
C02 Fgf13  Fibroblast growth factor 13 
C03 Fn1  Fibronectin 1 
C04 Gabbr2  Gamma-aminobutyric acid (GABA) B receptor, 2 
C05 Gbe1  Glucan (1,4-alpha-), branching enzyme 1 
C06 Gpr37  G protein-coupled receptor 37 
C07 Gria3  Glutamate receptor, ionotropic, AMPA3 (alpha 3) 
C08 Hspa4  Heat shock protein 4 
C09 Htr2a  5-hydroxytryptamine (serotonin) receptor 2A 
C10 Kcnj6  Potassium inwardly-rectifying channel, subfamily J, member 6 
C11 Lrrk2  Leucine-rich repeat kinase 2 
C12 Mapk9  Mitogen-activated protein kinase 9 
D01 Mapt  Microtubule-associated protein tau 
D02 Ncoa1  Nuclear receptor coactivator 1 
D03 Nefl  Neurofilament, light polypeptide 
D04 Nfasc  Neurofascin 
D05 Nr4a2  Nuclear receptor subfamily 4, group A, member 2 
D06 Nrxn3  Neurexin III 
D07 Nsf  N-ethylmaleimide sensitive fusion protein 
D08 Nsg1  Neuron specific gene family member 1 
D09 Ntrk2  Neurotrophic tyrosine kinase, receptor, type 2 
D10 Opa1  Optic atrophy 1 homolog (human) 
D11 Pan2  
PAN2 polyA specific ribonuclease subunit homolog (S. 
cerevisiae) 
D12 Park2  Parkinson disease (autosomal recessive, juvenile) 2, parkin 
E01 Park7  Parkinson disease (autosomal recessive, early onset) 7 
E02 Pink1  PTEN induced putative kinase 1 
E03 Ppid  Peptidylprolyl isomerase D (cyclophilin D) 
E04 Prdx2  Peroxiredoxin 2 
E05 Psen2  Presenilin 2 
E06 Pten  Phosphatase and tensin homolog 
E07 Rgs4  Regulator of G-protein signaling 4 
E08 Rtn1  Reticulon 1 
E09 S100b  S100 protein, beta polypeptide, neural 
E10 Sept5  Septin 5 
E11 Skp1a  S-phase kinase-associated protein 1A 
E12 Slc18a2  Solute carrier family 18 (vesicular monoamine), member 2 
F01 Slc25a4  
Solute carrier family 25 (mitochondrial carrier, adenine 
nucleotide translocator), member 4 
F02 Slc6a3 
Solute carrier family 6 (neurotransmitter transporter, 
dopamine), member 3 
F03 Slit1  Slit homolog 1 (Drosophila) 
F04 Snca  Synuclein, alpha 
F05 Spen  SPEN homolog, transcriptional regulator (Drosophila) 
F06 Srsf7  Serine/arginine-rich splicing factor 7 
F07 Stub1  STIP1 homology and U-Box containing protein 1 
F08 Sv2b  Synaptic vesicle glycoprotein 2 b 
F09 Syngr3  Synaptogyrin 3 
F10 Syt1  Synaptotagmin I 
F11 Syt11  Synaptotagmin XI 
F12 Tcf7l2  Transcription factor 7-like 2, T-cell specific, HMG-box 
G01 Th  Tyrosine hydroxylase 
G02 Tpbg  Trophoblast glycoprotein 
G03 Uba1  Ubiquitin-like modifier activating enzyme 1 
G04 Ubc  Ubiquitin C 
G05 Ube2i  Ubiquitin-conjugating enzyme E2I 
G06 Ube2k  Ubiquitin-conjugating enzyme E2K (UBC1 homolog, yeast) 
G07 Ube2l3  Ubiquitin-conjugating enzyme E2L 3 
G08 Uchl1  Ubiquitin carboxy-terminal hydrolase L1 
G09 Usp34  Ubiquitin specific peptidase 34 
G10 Vamp1  Vesicle-associated membrane protein 1 
G11 Vdac3  Voltage-dependent anion channel 3 
G12 Ywhaz  
Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein, zeta polypeptide 
H01 Actb  Actin, beta 
H02 B2m  Beta-2 microglobulin 
H03 Gapdh  Glyceraldehyde-3-phosphate dehydrogenase 
H04 Gusb  Glucuronidase, beta 
H05 Hsp90ab1  Heat shock protein 90 alpha (cytosolic), class B member 1 
H06 MGDC  Mouse Genomic DNA Contamination 
H07 RTC  Reverse Transcription Control 
H08 RTC Reverse Transcription Control 
H09 RTC Reverse Transcription Control 
H10 PPC  Positive PCR Control 
H11 PPC  Positive PCR Control 
H12 PPC  Positive PCR Control 
Western blot analyses 
Proteins were obtained by lysis or omogenization of (106) cells or brain tissue (5-10 
mg wet tissue) respectively, in RIPA buffer and quantified by BCA. Then 30 µg of 
protein were denatured in 8% SDS and 5% β-mercaptoethanol at 95°C for 5 min. 
After separation by SDS-PAGE on a 4-15% gel, or on a 3-8% Tris Acetate gel (for 
high weight proteins) under denaturing conditions, the proteins were 
electrotransferred to nitrocellulose membranes. The membranes were blocked with 
5% non-fat dry milk in TBS and then incubated overnight with anti-NAPE-PLD 
(1:200, #ab95397, Abcam, UK), anti-LRRK2 (1:5000, #ab133474, Abcam, UK), anti-
Rac1 (1:1000, #ab33186, Abcam, UK), anti-active Rac1 (1:1000, New East 
Biosciences, Malvern, USA), anti-FAK (1:1000, ZF002, Thermo Fisher, Rockford, 
USA), in 1% non-fat dry milk TBS containing 0.1% Tween-20, followed by incubation 
with horseradish peroxidase-linked anti-mouse or anti-rabbit IgG antibody (Millipore 
1:5000 dilution) in TBS 0.1% Tween 20 at room temperature for 1 h. Finally, proteins 
were visualized using an ECL Kit (Bio-Rad, USA), and the chemiluminescence 
image was obtained using a LAS-4000 lumino-image analyzer system (Fujifilm, 
Tokyo, Japan). To control for protein loading, the membranes were then stripped 
and reprobed with a monoclonal antibody raised against GAPDH (1:2000, #ab9485, 
Abcam). 
Lipid extraction and NAPE and FAE analysis 
Tissue NAPE levels were quantified as previously described13. Briefly cell pellets 
were subjected to sonication and frozen caudate putamen were weighed 
(approximately 10 mg) and homogenized using a chloroform:methanol mixture (1:2 
v/v, 2 ml) containing NAPE 18:0-22:6-17:1 and deuterated FAE (d4-OEA, d4-PEA 
and d3-SEA) as internal standards. After mixing for 30s, chloroform (0.6 mL) and 
water (0.6 mL) were sequentially added and vortexed after each addition. The 
samples were then centrifuged for 15 min at 3000xg at 4°C. After centrifugation, the 
aqueous (upper) and organic (lower) phase were separated by a protein disk. The 
organic phase was transferred to glass vials. For better extraction, the aqueous 
fraction was extracted again with chloroform (1 mL). Both the organic phases were 
pooled, dried under N2. The organic extracts from brain tissues were suspended in 
chloroform (2 mL) and fractionated by silica gel column chromatography. NAPEs 
were eluted with chloroform/methanol (1:1, v/v). Organic phases were evaporated 
under nitrogen and reconstituted in 100 μL of methanol:chloroform (9:1, v/v). LC/MS 
analyses were conducted on a Xevo TQ UPLC-MS/MS system (Waters) equipped 
with a reversed phase HSS T3 column (2.1 x 50 mm) (Waters, Milford MA), using a 
gradient elution at a flow rate of 0.4 mL/min. The mobile phase consisted of 10 mM 
ammonium formate in acetonitrile/water (60:40 v/v) as solvent A and 10mM 
ammonium formate in acetonitrile/isopropyl alcohol (10:90 v/v) as solvent B. MRM 
transition for all the metabolites are reported in table 2. The capillary voltage was set 
at 3kV. The cone voltage was set at 25V. The source temperature was set at 120°C. 
Desolvation gas and cone gas (N2) flow were set to 800 and 20 l/h respectively. 
Desolvation temperature was set to 450°C. Detection and analysis were controlled 
by Waters MassLynx software version 4.1. Calibration curves were prepared for 
every experiment (0.1 nM to 100 nM). 










P18:0-22:6-N16:0 1014.8 282.3/635.5 25 20 
P16:0-22:6-N18:0 1014.8 310.3/607.5 25 20 
18:0-22:6-N16:0 1030.8 282.3/651.5 25 20 
16:0-22:6-N18:0 1030.8 310.3/623.5 25 20 
18:0-20:4-N18:0 1034.8 310.3/627.5 25 20 
P18:0-22:6-N18:0 1042.8 310.3/635.5 25 20 
18:0-22:6-N18:0 1058.8 310.3/651.5 25 20 
18:0-22:6-N17:0 1044.6 296.4/651.5 25 20 
OEA 326 62 20 30 
PEA 300 62 20 30 
SEA 328 62 20 30 
D4-OEA 330 66 20 30 
D4-PEA 304 66 20 30 
D3-SEA 331 62 20 30 
Activated caspase-3 ELISA 
ELISA kit (R&D, Abingdon, UK) was used to measure activated Caspase-3 levels in 
SH-SY5Y cells. The assay was performed according to the manufacturer's 
instructions. Briefly, cells were grown in 6 multi-well plates, 1 h before the 6-OHDA 
time-point cells were treated with biotin-ZVKD-fmk inhibitor (1.4 μL), then cells were 
scraped with extraction buffer and stored at 4°C. 100 μL of each sample were 
loaded on the ELISA plate and incubated for 2 h at room temperature. Then active 
Caspase-3 conjugate was added to the plate and incubate for 1 h, after that 
substrate solution was added to each well and incubated for 30 min. Finally stop 
solution was added and the optical density of each well was determined using a 
micro-plate reader (Tecan, Mannedorf, Switzerland) set to 450 nm.  
Intracellular ROS measurement 
Relative changes in intracellular ROS in the SH-SY5Y cells were monitored using a 
fluorescent probe DCFH-DA (Abcam). Cells were grown in 24 multi-well plates and 
before the treatment with 6-OHDA, cells were incubated with 5 μM DCFDA for 1 h at 
37°C. At the end of the treatment with 6-OHDA cells were harvested, transferred to 
a black multi-well plates and fluorescence was measured using a Tecan microplate 
reader with excitation-emission set to 485-535 nm.  
Immunohistochemistry 
Mice were anesthetized with chloral hydrate (400 mg/kg), and transcardially 
perfused with 40 mL of saline solution followed by 40 mL of 4% paraformaldehyde. 
Tissue was postfixed in paraformaldehyde 4% for 1 h and then stored in 30% 
sucrose for 3 days before being frozen in liquid nitrogen. Forty micrometer sections, 
one every third, were collected and processed for immunohistochemistry. In order to 
verify the degeneration of dopaminergic neurons, tissue immunostaining was 
performed by section incubation with an anti-tyrosine hydroxylase antibody (TH; 
1:500; Abcam, UK) followed by incubation with Alexa fluor 546 (1:1000; Life 
Technologies, USA). Images were collected using a Nikon A1 confocal microscopy 
with a 10X magnification and a 1.4 numerical aperture objective lens. Intensity of 
fluorescence measurements were performed with ImageJ. The corrected total cell 
fluorescent was calculated according to the following formula: Integrated Density – 
(Area of selected cell x Mean fluorescence of background readings).  
Stereology 
Quantitative estimation of TH-positive neurons was performed in every 6th section of 
the SNpc. The unbiased sampling and blinded stereological counting were done 
using the optical fractionator probe in Stereo Investigator software (MBF Bioscience, 
USA). The parameters used include a counting frame size of 60 x 60, a sampling 
site of 100 x 100 and a dissector height of 15 µm. A total of 3 to 4 animals per group 
were used and 4 sections per animal were counted. 
Turning behaviour 
Three weeks post-surgery all subgroups of mice received an injection of 
apomorphine (0.5 mg/kg in 0.2% ascorbic acid, i.p., Sigma, Milan, Italy) to evaluate 
the extent of nigrostriatal lesion. Rotational behavior was measured by placing 
animals in a circular cage where their behavior was recorded for 1 h and 15 min, 
using a tracking software (Anymaze, Dublin, Ireland). The total number of rotations 
during the test was used for analysis. 
Statistics  
GraphPad Prism software V5.03 (GraphPad Software, Inc., USA) was used for 
statistical analysis. Data were analyzed using the Student t-test, One-way ANOVA 
or Two-way ANOVA followed by Bonferroni or Dunnet post hoc test for multiple 
comparisons. Differences between groups were considered statistically significant at 
values of p < 0.05. Results are expressed as mean ± S.E.M. 
  
RESULTS 
6-OHDA lowers NAPE-PLD expression and increases NAPE levels in SH-SY5Y 
cells 
We first evaluated 6-OHDA toxicity on the human neuroblastoma SH-SY5Y 
cell line. These cells can be used in their undifferentiated form or they can be 
differentiated in a more pronounced neuronal phenotype. Both cases present 
advantages and limitations as discussed in the introduction97. We decided to use 
undifferentiated SH-SY5Y cells for two reasons: first, the differentiation process 
introduces a great variability between different experiments; second, undifferentiated 
SH-SY5Y cells already express dopaminergic markers such as tyrosine hydroxylase 
(TH), dopamine β hydroxilase and dopamine transporter (DAT), necessary for 
dopamine (DA) incorporation, in a uniform fashion. 
Thus, we treated SH-SY5Y cells with 100 M 6-OHDA and we measured the effects 
of the neurotoxin at different time-points. The first measure of 6-OHDA toxicity was 
the increase in ROS production. As shown in Fig. 7 A, ROS increase was already 
significant 2 h after 6-OHDA administration. This data was accompanied by a slower 
increase of Caspase 3 activation starting 6 h post drug administration (Fig. 7 B). 
Previous work has shown that NAPEs are increased after noxious stimuli (see 
introduction), thus I analyzed levels of these lipid mediators. As expected, 6-OHDA 
toxicity was accompanied by an increase in diverse species of NAPE, mainly 
species with a long polyunsaturated chain in the sn2 position (Fig. 7 C), which are 
PEA and SEA precursors. NAPE increase was accompanied by a progressive 
reduction in both mRNA and protein expression of NAPE-PLD, the enzyme that 
catalyses NAPE hydrolysis (Fig. 7 D-E).  
 Figure 7: Time-course of the effect of 100 μM 6-OHDA on SH-SY5Y cells. (A) ROS, (B) Active 
Caspase-3, (C) NAPEs levels; (D) NAPE-PLD mRNA expression levels; (E) NAPE-PLD protein 
expression. All histograms represent the mean +/- SEM of 6-9 determinations from three independent 
experiments. *p<0.05, **p<0.01, ***p<0.001. One-Way ANOVA followed by Bonferroni’s test. 
  
NAPE-PLD silencing protects SH-SY5Y cells from 6-OHDA toxicity  
To address whether NAPEs have a protective or noxious effect on neuronal 
viability, I used a small interference RNA technique to induce NAPE-PLD mRNA 
down-regulation , which was effectively reduced by 61% (Fig. 8 A). SHSY5Y cells 
are not widely used for this technique, as neurons are not so prone for transfection, 
thus we consider a downregulation of 60% a good result, comparable to the 70% 
efficiency suggested by the manufacturer’s protocol. 
6-OHDA induced a higher increase in NAPE levels in NAPE-PLD silenced cells 
when compared to control cells (Fig. 8 B) without affecting FAE levels (Fig. 8 C). At 
a functional level, NAPE-PLD silenced cells produced less ROS (Fig. 8 D), and a 
weaker activation of Caspase 3 (Fig. 8 E) than did control cells. As a consequence, 
cell death was reduced in silenced cells compared to naïve cells (Fig. 8 F); thus, 
NAPE species can reduce 6-OHDA-induced toxicity in SH-SY5Y cells. We then 
confirmed the protective role of NAPEs, using a pharmacological approach: we 
treated SH-SY5Y cells with ARN19874, a NAPE-PLD inhibitor developed in our 
laboratory. Cells were pre-treated with ARN19874 (50 M) 2 h before 6-OHDA 
administration and then counted after 8 h of 6-OHDA treatment. As expected, 
NAPE-PLD inhibition produces an effect similar to that of NAPE-PLD silencing, 
leading to an increase in the number of viable cells (Fig. 8 G). In contrast when 
NAPE-PLD is overexpressed (Fig. 8 A), SH-SY5Y cells were more sensitive to 6-
OHDA toxicity (Fig. 8 H), confirming the protective role of NAPEs. 
 Figure 8: Effect of NAPE-PLD silencing in 100 μM 6-OHDA treated SH-SY5Y cells. (A) NAPE-PLD 
mRNA expression after silencing and overepression; (B) NAPE and (C) FAE levels measured 8h after 
the treatment; (D) ROS and (E) Active Caspase-3 levels respectively 8 and 6 h after treatment; cell 
viability in NAPE-PLD silenced cells (F), in cells pre-treated with ARN19874 (G), and in NAPE-PLD 
overexpressing cells (H). All histograms represent the mean +/- SEM of 6-9 determinations from three 
independent experiments. In white vehicle, in blue 6-OHDA treated naïve cells, in red 6-OHDA treated 
silenced/inhbited/overexpressed cells. *p<0.05, **, p<0.01, ***p<0.001 comparing 6-OHDA to control, 
°p<0,05, °°p<0,01, °°°p<0,001 comparing siRNA to Control. Two-Way ANOVA followed by Bonferroni’s 
test. 
 
NAPE-PLD deletion protects from 6-OHDA toxicity in a mouse model of Parkinson’s 
disease 
We next moved to an in vivo approach, using NAPE-PLD-/- mice. We have 
already shown that specific NAPE species are increased after unilateral 
administration of 6-OHDA in the CPu of mice13: these lipid molecules show 
saturated or mono-unsaturated acyl chains in the sn1 position, long polyunsaturated 
chains in the sn2 position, and are mainly PEA and SEA precursors. Thus, using the 
same model, we investigated the role of these molecules using NAPE-PLD-/- mice28. 
Briefly, we injected 3.2 mg/ml of 6-OHDA in two areas of the Caudate of mice. We 
then collected CPu and SNpc from lesioned or control side of the brain 48 h or 3 
weeks after lesion. 48 h after drug administration, NAPE-PLD-/- mice showed a basal 
increase in NAPE levels (Fig. 9 A-B) and, as expected, treatment with 6-OHDA 
induced an additional increase in these lipids in the CPu (Fig. 9 B). Three weeks 
after 6-OHDA injection, when the pathology is fully developed, we conducted 
histological studies on the brains of NAPE-PLD-/- mice and wild type littermates. CPu 
and SNpc were stained with anti-Tyrosine Hydroxylase (TH) antibody. TH is 
expressed specifically in dopaminergic neurons, thus TH staining represents a good 
approach to measure dopaminergic neurodegeneration. NAPE-PLD-/- mice showed 
a reduction in the degeneration of dopaminergic neurons in the substantia nigra pars 
compacta compared to wild type mice (Fig. 9 C-E); this effect was further quantified 
through the count of TH positive neurons using a stereological approach, which 
allows to obtain an unbiased and quantitative estimation of the number of specific 
objects, through the use of random and systematic sampling. This technique 
highlights protective effect of NAPE-PLD deletion (Fig. 9 G): wild type littermates 
lost 69% of dopaminergic neurons in the SNpc, whereas NAPE-PLD-/- mice lost only 
20% of TH positive neurons. Moreover, unilateral lesion induces an imbalance in the 
dopaminergic system between control and lesion side of the brain, which can be 
quantified by administration of apomorphine, a dopaminergic agonist. This 
compound induced vigorous ipsilateral rotations, because of hypersensitivity of the 
dopaminergic receptors in the lesioned emisphere. The number of rotations is 
directly proportional to the magnitude of the lesions. Thus, using this technique we 
observed a 51% reduction in the number of rotations induced by apomorphine in 
NAPE-PLD-/- mice compared to wild-type mice (Fig. 9 H).  
 
 Figure 9: Protective effect of NAPE-PLD depletion in 6-OHDA mice model. (A-B) NAPEs levels in 
wild type mice treated with 6-OHDA (A) compared to NAPE-PLD
-/-
 mice (B).  (C-F) Staining for TH 
(Red) and DAPI (Blue) in contralateral side brain (Control) or ipsilateral side brain (Lesion) of WT mice 
(C, E), compared to contralateral side brain or ipsilateral side brain of NAPE-PLD KO mice (D, F). (G) 
Count of TH+ neurons, (H) Number of apomorphine induced rotation in NAPE-PLD
-/-
  mice compared 
to WT mice. All histograms represent the mean +/- SEM of 3-9 determinations from three independent 
experiments. *p<0.05, **p<0.01, ***p<0.001; °°p<0.01 comparing WT versus KO.  Student’s t test or 
Two-Way ANOVA followed by Bonferroni’s test. 
  
In the CPu, 3 weeks post surgery, we observed an increased number of 
dopaminergic fibers in NAPE-PLD-/- mice (Fig. 10 A-D); indeed, the quantification of 
fluorescence intensity (Fig. 10 E) showed that wild type mice lost 61% of the 
dopaminergic fibers in the CPu, while NAPE-PLD-/- mice only 26%. Taken together, 
these data suggest that NAPE species have a protective role during the 
neurodegenerative process. 
 
Figure 10: Protective effect of NAPE-PLD depletion in 6-OHDA mice model. (A-D) Staining for TH 
(Red) and DAPI (Blue) in contralateral side brain (Control) or ipsilateral side brain (Lesion) of WT mice 
(A,C), compared to contralateral side brain or ipsilateral side brain of NAPE-PLD KO mice (B,D). (E) 
intensity of fluorescence of TH staining in the Caudate Putamen of NAPE-PLD
-/-
 control and lesion side 
brain, compared to wild type mice. All histograms represent the mean +/- SEM of 19-26 determinations 
from three independent experiments. *p<0.05, **p<0.01, ***p<0.001; °p<0.05, °°p<0.01, °°°p<0,001 
comparing WT versus KO. Two-Way ANOVA followed by Bonferroni’s test. 
  
NAPE-PLD deletion is linked to peculiar genic modifications that may be involved in 
neuroprotection 
 To explore the mechanisms underlying neuroprotection in NAPE-PLD-/- mice, 
I used a RT² Profiler™ PCR Array approach. Briefly, mRNA obtained from control 
and lesioned side SNpc, collected 48 h post 6-OHDA administration, was amplified 
on a commercial mRNA array plate containing primers for genes directly or 
potentially involved in PD etiology. This technique led me to assess mRNA 
expression changes between WT and KO mice in response to 6-OHDA-induced 
toxicity. 
The analysis was designed to reveal separately possible differential effects of 6-
OHDA on the two strains (Fig. 11 A, B respectively). Statistical analysis revealed 
multiple but significant differences in PD-related gene expression between the 
lesioned side and control side of the two groups. Among 84 assayed genes, 25 were 
shown to be regulated in an opposite direction in the two strains, as reported in 
Table 3. In particular, only 15 genes (Fig. 11 C,D) showed a difference of at least 
25% in expression between lesioned sides of the two strains. Considering functional 
gene groups assayed, the most abundant gene expression changes were observed 
for genes related to cell adhesion (Apc, App, Cdh8, Nfasc, Fn1), cytoskeletal 
organization (Apc, PARK2, Mapt), ubiquitination (LRRK2, PARK2, PINK1), 
mitochondria (LRRK2, PINK1, Casp7) and membrane transport (Syt11, Egln1, 
Slc18a2). However, most of the genes are known to be involved in more than one 
process. It is worth of note that three genes related to genetic and sporadic PD 
(LRRK2, PARK2 and PINK1) were regulated in an opposite way in the two strains. 
In particular, PARK2 and PINK1, which are characterized by a loss of function in the 
pathology of PD, were down-regulated in WT mice (-48% and -20% respectively), 
while slightly up-regulated in KO mice (+9%); moreover, two substrates of PARK2-
mediated ubiquitination (Atxn3, Syt11) were downregulated in WT mice after the 
lesion (-25% and -29%), and slight up-regulated in KO mice (+10% and +7%). 
Lastly, LRRK2 is known to be mutated in a gain of function fashion in many PD 
cases: in accordance, WT mice up-regulated this gene in response to 6-OHDA 
administration (+15%); in contrast, KO mice markedly down-regulated the gene by 
50%.  
  
Table 3: PD related genes expression fold change in NAPE- PLD
-/-  
and WT mice 48h after 6-
OHDA administration. FR fold regulation. P value calculated by Student’s t test, with n=3. 
Gene symbol FR WT % WT p value FR KO % KO p value 
Apc -1.45 -45% 0.046506 1.12 +12% 0.647152 
App -1.23 -23% 0.014865 1.06 +6% 0.828518 
Atp2b2 -1.03 -3% 0.765594 1.09 +9% 0.841150 
Atxn3 -1.25 -25% 0.030927 1.10 +10% 0.706594 
Casp1 -1.05 -5% 0.702875 1.11 +11% 0.860526 
Casp 7 -1.30 -30% 0.379677 1.05 +5% 0.893019 
Casp9 -1.42 -42% 0.006829 1.06 +6% 0.932468 
Cdh8 1.07 +7% 0.613042 -1.52 -52% 0.294888 
Egln1 -1.21 -21% 0.036793 1.03 +3% 0.954444 
Fbxo9 -1.14 -14% 0.141198 1.00 0% 0.975173 
Fn1 -1.34 -34% 0.108515 1.23 +23% 0.656451 
Gbe1 -1.07 -7% 0.550695 1.09 +9% 0.269209 
Hspa4 -1.20 -20% 0.068983 1.05 5% 0.601453 
LRRK2 1.15 +15% 0.351875 -1.50 -50% 0.102601 
Mapt -1.22 -22% 0.012189 1.05 +5% 0.631354 
Nfasc -1.14 -14% 0.103517 1.31 +31% 0.174574 
Park2 -1.48 -48% 0.092555 1.09 +9% 0.797287 
PINK1 -1.20 -20% 0.100158 1.09 +9% 0.774096 
Prdx2 -1.08 -8% 0.281470 1.01 +1% 0.947735 
Slc18a2 1.71 +71% 0.742609 -1.16 -16% 0.584880 
Slc25a4 -1.08 -8% 0.431641 1.03 +3% 0.760694 
Syt11 -1.29 -29% 0.007682 1.07 +7% 0.893016 
Uba1 -1.15 15% 0.339637 1.03 +3% 0.582091 
Ubc -1.14 14% 0.215492 1.07 +7% 0.619278 
Vamp1 1.00 0% 0.929908 -1.15 -15% 0.612199 
 
 
 Figure 11: Different gene regulation in NAPE- PLD
-/-  
and WT mice 48h after 6-OHDA 
administration. Heatmap of gene regulation in WT mice (A) and NAPE- PLD
-/- 
mice (B) after 6-OHDA 
administration compared to control side brains. (C,D) Fold regulation change expression of genes 
involved in cell adhesion, cytoskeletal organization and ubiquitination (C) or in transport, apoptosis and 






NAPE-PLD-/- mice show a downregulation of LRRK2 pathway  
 To further verify PARK2, PINK1 and LRRK2 expression in NAPE-PLD-/- and 
wild type mice, I run an RT-PCR analysis on samples collected 48 h post lesion. The 
results did not reveal any statistically significant change in LRRK2 transcriptions 
between lesioned and unlesioned side of WT mice (Fig. 12 A), while showing a 
significant upregulation of PARK2 in NAPE-PLD-/- lesioned mice and only a positive 
trend in the control side (Fig. 12 B). No effect of the lesion on NAPE-PLD deletion 
was seen in the levels of PINK1transcription (Fig. 12 C). 
Given the strict association of LRRK2 with membranes, I finally focused my attention 
on this protein. LRRK2 is a large ubiquitous cytoplasmic protein with multiple 
functional domains, encompassing two enzymatic functions at its core: GTPase and 
kinase activities. It participates in a range of cellular processes such as vesicular 
trafficking, cytoskeletal dynamics, mitochondrial function and autophagy98. As 
already mentioned, LRRK2 mutations are common in sporadic and familiar PD, in 
particular, the dominant pathogenic mutations described up to date occur within the 
enzymatic core of this protein, leading to a gain of function.  
This protein mediates its function regulating diverse signaling cascades. Indeed, 
LRRK2 is known to bind multiple small GTPases such as Rho GTPase proteins. 
Among other proteins it binds Rac1, regulating positively the site of action of this 
small GTPase99. 
Rac1 (Ras-related C3 botulinum toxine substrate 1) is a signaling GTPase, 
belonging to the Ras superfamily. This protein is known to be involved in many 
cellular processes, including cell growth, cytoskeletal reorganization cell adhesion 
and motility. Furthermore it is known to be involved in the regulation of cell fate in 
neurodegeneration100. 
Western blot analyses on lesioned and control SNpc isolated 48 h post 6-OHDA 
administration were performed in both WT and KO mice. Interestingly, LRRK2 
protein expression was strongly downregulated in the control side of KO mice 
compared to WT mice, with a decrease of about 52% (Fig. 12 D). LRRK2 
downregulation was accompanied by an increase in total Rac1 expression in KO 
mice (Fig. 12 E), but not in activated Rac1 (Rac1-GTP in Fig. 12 F). Indeed, Fig. 12 
G shows the rate between total Rac1 and Rac1-GTP, confirming the inhibition of 
Rac1 activity in KO mice. Moreover, Focal adhesion kinase (FAK-1), another protein 
known to stimulate Rac1 activity, was also down-regulated in NAPE-PLD-/- mice (Fig. 
12 H).  
 Figure 12: NAPE-PLD depletion leads to a downregulation of LRRK2 pathway. LRRK2 (A), 
PARK2 (B), PINK1 (C) mRNA expression levels in the control (white) or lesioned side of substantia 
nigra in NAPE-PLD
-/- 
and WT mice (respectively red and blue). LRRK2 (D), Rac1 (E), Rac1-GTP (F) 
and FAK1 (H) protein levels, measured by western blot in control and lesioned side brain of NAPE-
PLD
-/- 
and WT mice. (G) Rate of Rac1-GTP on total Rac1. All histograms represent the mean +/- SEM 
of 6 determinations from three independent experiments. *p<0.05, **p<0.01; °p<0.05, °°p<0,01 
comparing WT versus KO Two-Way ANOVA followed by Bonferroni’s test.  
  
DISCUSSION 
 NAPEs have been primarily conceptualized as precursors for bioactive 
FAEs, such as anandamide and PEA. Only in the last decade, the scientific 
community has started to think about NAPEs as lipid mediators with specific 
functions, separate from those of FAEs, such as membrane stabilization, anchorage 
or activation of peripheral membrane proteins and organization of cell division sites5. 
NAPEs accumulate in the brain after injury. 
In the present work, I investigated the role of these membrane compounds in the 
neurodegenerative process that underlies PD progression. To do so, I first focused 
my attention on a cellular model of PD, in which I confirmed increased NAPEs 
production after 6-OHDA administration. Moreover, impairment of the respiratory 
mechanism leads to an increase of intracellular calcium, which could stimulate the 
activity of Ca-NAT, the enzyme that produces NAPEs.  
Unfortunately, Ca-NAT has not yet been isolated and characterized, so we can only 
manage indirectly NAPEs accumulation, through the inhibition of the downstream 
metabolism of NAPEs. Thus, using a genetic approach, I demonstrated that NAPEs 
have a protective role in SH-SY5Y cells. Indeed, silencing of NAPE-PLD, the main 
enzyme involved in NAPE degradation, induced a further increase in NAPEs but not 
in FAE levels, protecting cells from 6-OHDA induced toxicity.  
Here, I demonstrated for the first time that NAPEs are produced in a cellular model 
of PD; moreover, we have recently observed that particular species of NAPEs are 
produced also in vivo, in a mice model of PD, following administration of 6-OHDA in 
the CPu13.  
From this starting point, I next demonstrated that NAPE-PLD-/- mice show a 
reduction in the neurodegenerative process, compared to WT mice. Indeed, the 
stereological count of TH positive neurons and dopaminergic fibers, together with 
behavioral tests confirm the protective role of NAPEs. In particular, NAPE-PLD-/-  
mice showed a baseline increase in all NAPE species analyzed, but 6-OHDA 
treatment induced a further increase in specific NAPE compounds; namely PEA and 
SEA precursors (with 16:0 or 18:0 chain in the sn3 position, respectively) and long 
polyunsaturated carbons chains (mainly 22:6) in the sn2 position. 
The baseline increase in NAPE levels is accompanied by a substantial difference in 
gene expression between NAPE-PLD-/- mice and their WT littermates. This is the 
reason why analyzing data from mRNA array panel, I decided to consider separately 
the two strains of mice, comparing gene expression in lesioned brain side versus 
control side brain.  
Among the 15 genes that were regulated in an opposite fashion in the two strain, 
some of them are poorly characterized in PD: Cadherin 8 is only known to be 
overexpressed in LUHMES cells treated with 6OHDA101; Fibronectin 1 is reported to 
represents a protective factor in PD. In both cases our data fit with these evidences, 
indeed Cdh8 is downregulated in WT mice and upregulated in KO mice, while Fn 1 
showed an opposite behavior.  
Other genes are better characterized in relation to PD, but the literature reports 
controversial data; for instance, Ataxin 3 is reported to be upregulated in human 
SNpc from PD patients102 and in PC12 cells treated with 6OHDA103, while is 
downregulated in LUHMES cells treated with 6-OHDA101 as in our model. Caspase 9 
is known to be overexpressed in MPTP- or rotenone-treated mice104,105,  but is 
downregulated in SH-SY5Y cells treated with paraquat106. My data are in 
accordance with the latter paper: WT mice showed downregulation of Caspase 9, 
while KO mice slight up-regulated it.  
Caspase 7, Egln1 and Slc18a2 are differentially regulated in NAPE-PLD-/-  mice, 
comparing to previous data; indeed Caspase 7 and Egln1 are upregulated in a 
variety of models101, 103, 106,107 , while Slc18a2 is known to be downregulated101,108. 
Moreover, data obtained from mRNA arrays highlighted a peculiar difference 
between NAPE-PLD-/- mice and WT in 3 genes that are strongly linked with PD: 
PARK2, PINK1 and LRRK248. PARK2 encodes for parkin, an ubiquitin ligase 
protein, while PINK1 correspond to the PTEN induced putative kinase 1; these 
proteins are involved in a quality control pathway that maintains mitochondrial 
homeostasis in many cell types, including dopaminergic neurons, whose malfunction 
causes PD109. Indeed, both these proteins are mutated in many cases of early-onset 
familial PD. Generally, mutations determine a loss of function in these proteins, 
leading to an impairment of the ubiquitin-proteasome pathway110. Thus, 
overexpression of PARK2 and PINK1 have a protective effect on 6-OHDA induced 
toxicity111,112. In our model PARK2 and PINK1 are downregulated in WT mice 
treated with 6-OHDA, while slightly up-regulated in NAPE-PLD-/- mice. PARK2 
upregulation in the lesioned side of NAPE-PLD-/- mice was further confirmed by RT-
PCR. Consistent with our observations, these two proteins were down-regulated in 
LUHMES cells treated with 6-OHDA101. Moreover, PINK1 is known to be 
downregulated in the SNpc of subjects with PD113. We may speculate that parkin 
and PINK1 up-regulation in NAPE-PLD-/- mice participate in the neuroprotective 
effects of NAPEs. 
Interestingly, a combined analysis obtained using two different softwares that 
illustrate known protein-protein interactions, available online (https://thebiogrid.org 
and http://string-db.org), showed that some of the proteins coded by the genes 
highlighted by the arrays are linked together (Fig. 13). I chose to focus my attention 
on a smaller set of proteins because our data are in agreement with the literature, 
and these genes are already well characterized in PD. Probably, the beneficial effect 
induced by NAPEs is the readout of a complex interaction between all these 
proteins, rather than the result of a single protein modulation. 
 
Figure 13: Protein-protein interaction analysis. Protein regulated in an opposite fashion in NAPE-
PLD
-/- 
and WT mice that  are linked by interactive capability. The software I adopted, run their analysis 
using databases that analyze the whole literature. The more is thick the line between two proteins, the 
more their interaction is consistent. 
The LRRK2 gene encodes for LRRK2 protein also known as Dardarin, a large 
multifunctional protein containing diverse domains; including a kinase domain and a 
GTPasic core. LRRK2 is known to have many functions in the cells, mainly related 
to cellular trafficking and regulation of actin dynamics114. LRRK2 is mutated in a 
consistent number of PD patients, with the most common abnormalities determining 
a gain of function of the protein, and affecting either the kinase domain or the 
GTPase portion115.  
Our arrays studies highlighted differential regulation of LRRK2: it is slightly 
upregulated in the lesioned side of WT mice, whereas it is downregulated in NAPE-
PLD-/- lesioned side. However, when we quantified protein expression, surprisingly 
the protein appeared to be strongly downregulated in unlesioned KO mice compared 
to WT. Given the fact that LRRK2 is frequently associated with cellular membranes, 
we speculate that enrichment of membranes in NAPE content leads to a minor 
binding capability of LRRK2, which accumulates in the cytosol and is degraded. We 
are currently testing this hypothesis. 
LRRK2 is known to bind and activate Rac199, a small GTPase that has been shown 
to be inhibited by NAPE32. In NAPE-PLD-/- mice, it seems that lack of LRRK2 
determines an inhibition in Rac1 activity, but not a reduction in the total form of Rac1 
protein, which appears to be upregulated, maybe as a compensation effect. 
Rac1 is involved in a variety of functions such as cell growth, cytoskeletal 
reorganization, cell adhesion and motility. In neurodegeneration, the role of Rac1 
activity is controversial: it is reported that its activation leads to the activation of the 
ERK/MAPK and PI3K/AKT pathways, which both determine activation of pro-
survival Bcl-2 family and inhibition of pro-apoptotic Bcl2 family. At the same time, it 
is also known that Rac1 activation leads to the stabilization of the NADPH oxidase 
on cell membranes, determining ROS production100. 
On the basis of my results, Rac1 could be involved in NADPH oxidase stabilization 
in the SNpc, thus if inhibited leads to the reduction of ROS production, as we have 
already observed in NAPE-PLD silenced SH-SY5Y cells. 
Consistent with this hypothesis, it is known that Rac1 mediates noxious effect in 
neurodegeneration both in vitro as in vivo116: SH-SY5Y cells treated with 
glutamate117 or in the presence of proinflammatory cytokines118 showed 
translocation of Rac1 to the plasma membrane, subsequent stabilization of NADPH 
oxidase, cytoskeleton reorganization and ROS induced cell death. The same 
pathway has been observed also in ischemic mice119,120, where the inhibition of 
Rac1 appears to be protective from neurodegeneration. 
In our models, Rac1 inhibition could be mediated by both LRRK2 and FAK1, given 
the fact that both this proteins impact Rac1 activation99,121 and are inhibited or 
downregulated in NAPE-PLD-/-mice. 
In conclusion, our multidisciplinary experiments provide strong evidence that NAPEs 
play a protective role in the response to 6-OHDA induced toxicity. Indeed, NAPEs 
induce changes in gene expression that could cooperate in mediating 
neuroprotective effects. In particular, NAPEs lead to LRRK2 downregulation and 
consequent Rac1 inhibition, possibly determining a reduction in ROS production. 
This work could represent the starting point for the development of new therapeutic 
approaches and identification of new biological markers for neurodegenerative 
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